7. REFERENCES
1.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
2.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
3.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
4.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
5.Abrams, P., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn, 2002. 21: 167.
https://pubmed.ncbi.nlm.nih.gov/11857671/
6.Martin, S.A., et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol, 2011. 29: 179.
https://pubmed.ncbi.nlm.nih.gov/20963421/
7.Société Internationale d’Urologie (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS. , C. Chapple & P. Abrams, Editors. 2013.
8.Kupelian, V., et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med, 2006. 166: 2381.
https://pubmed.ncbi.nlm.nih.gov/17130393/
9.Agarwal, A., et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol, 2014. 65: 1211.
https://pubmed.ncbi.nlm.nih.gov/24486308/
10.De Ridder, D., et al. Urgency and other lower urinary tract symptoms in men aged >/= 40 years: a Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. Int J Clin Pract, 2015. 69: 358.
https://pubmed.ncbi.nlm.nih.gov/25648652/
11.Taub, D.A., et al. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep, 2006. 7: 272.
https://pubmed.ncbi.nlm.nih.gov/16930498/
12.Gacci, M., et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int, 2015. 115: 24.
https://pubmed.ncbi.nlm.nih.gov/24602293/
13.Gacci, M., et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. Eur Urol, 2016. 70: 788.
https://pubmed.ncbi.nlm.nih.gov/27451136/
14.Kogan, M.I., et al. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin, 2014. 30: 2119.
https://pubmed.ncbi.nlm.nih.gov/24932562/
15.Chapple, C.R., et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol, 2008. 54: 563.
https://pubmed.ncbi.nlm.nih.gov/18423969/
16.Ficarra, V., et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep, 2014. 15: 463.
https://pubmed.ncbi.nlm.nih.gov/25312251/
17.He, Q., et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis, 2016. 19: 7.
https://pubmed.ncbi.nlm.nih.gov/26391088/
18.Drake, M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn, 2014. 33: 622.
https://pubmed.ncbi.nlm.nih.gov/24838519/
19.Chapple, C.R., et al. Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). Neurourol Urodyn, 2018. 37: 2928.
https://pubmed.ncbi.nlm.nih.gov/30203560/
20.Novara, G., et al. Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy. Eur Urol Suppl 2006. 4: 418.
https://www.sciencedirect.com/science/article/abs/pii/S1569905606000121
21.McVary, K.T., et al. Update on AUA guideline on the management of benign prostatic hyperplasia.
J Urol, 2011. 185: 1793.
https://pubmed.ncbi.nlm.nih.gov/21420124/
22.Bosch, J., et al. Etiology, Patient Assessment and Predicting Outcome from Therapy. International Consultation on Urological Diseases Male LUTS Guideline 2013. (In press).
23.Martin, R.M., et al. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer, 2008. 123: 1924.
https://pubmed.ncbi.nlm.nih.gov/18661522/
24.Young, J.M., et al. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int, 2000. 85: 1037.
https://pubmed.ncbi.nlm.nih.gov/10848691/
25.Bright, E., et al. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn, 2011. 30: 348.
https://pubmed.ncbi.nlm.nih.gov/21284023/
26.De Nunzio, C., et al. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus, 2017. 3: 352.
https://pubmed.ncbi.nlm.nih.gov/29191671/
27.Barqawi, A.B., et al. Methods of developing UWIN, the modified American Urological Association symptom score. J Urol, 2011. 186: 940.
https://pubmed.ncbi.nlm.nih.gov/21791346/
28.Barry, M.J., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 1992. 148: 1549.
https://pubmed.ncbi.nlm.nih.gov/1279218/
29.Donovan, J.L., et al. Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol, 2000. 164: 1948.
https://pubmed.ncbi.nlm.nih.gov/11061889/
30.Epstein, R.S., et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol, 1992. 45: 1431.
https://pubmed.ncbi.nlm.nih.gov/1281223/
31.Homma, Y., et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology, 2006. 68: 318.
https://pubmed.ncbi.nlm.nih.gov/16904444/
32.Schou, J., et al. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol, 1993. 27: 489.
https://pubmed.ncbi.nlm.nih.gov/7512747/
33.Homma, Y., et al. Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol, 2008. 15: 816.
https://pubmed.ncbi.nlm.nih.gov/18657204/
34.D’Silva, K.A., et al. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA, 2014. 312: 535.
https://pubmed.ncbi.nlm.nih.gov/25096693/
35.ICIQ. International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Module (ICIQ-MLUTS). 2022.
https://iciq.net/iciq-mluts-lf
36.Bryan, N.P., et al. Frequency volume charts in the assessment and evaluation of treatment: how should we use them? Eur Urol, 2004. 46: 636.
https://pubmed.ncbi.nlm.nih.gov/15474275/
37.Gisolf, K.W., et al. Analysis and reliability of data from 24-hour frequency-volume charts in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2000. 38: 45.
https://pubmed.ncbi.nlm.nih.gov/10859441/
38.Cornu, J.N., et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysio-logy, and management--a systematic review and meta-analysis. Eur Urol, 2012. 62: 877.
https://pubmed.ncbi.nlm.nih.gov/22840350/
39.Weiss, J.P. Nocturia: “do the math”. J Urol, 2006. 175: S16.
https://pubmed.ncbi.nlm.nih.gov/16458734/
40.Weiss, J.P., et al. Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn, 2012. 31: 330.
https://pubmed.ncbi.nlm.nih.gov/22415907/
41.Vaughan, C.P., et al. Military exposure and urinary incontinence among American men. J Urol, 2014. 191: 125.
https://pubmed.ncbi.nlm.nih.gov/23871759/
42.Yap, T.L., et al. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int, 2007. 99: 9.
https://pubmed.ncbi.nlm.nih.gov/16956355/
43.Bright, E., et al. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol, 2014. 66: 294.
https://pubmed.ncbi.nlm.nih.gov/24647230/
44.Weissfeld, J.L., et al. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials, 2000. 21: 390s.
https://pubmed.ncbi.nlm.nih.gov/11189690/
45.Roehrborn, C.G. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology, 1998. 51: 19.
https://pubmed.ncbi.nlm.nih.gov/9586592/
46.Roehrborn, C.G., et al. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology, 2001. 57: 1087.
https://pubmed.ncbi.nlm.nih.gov/11377314/
47.Bosch, J.L., et al. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol, 2004. 46: 753.
https://pubmed.ncbi.nlm.nih.gov/15548443/
48.Babjuk, M., et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer In: EAU Guidelines published at the 38th EAU Annual Congress, Milan 2023. Arnhem, The Netherlands.
https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
49.Bonkat, G., et al. EAU Guidelines on Urological Infections In: EAU Guidelines published at the 38th EAU Annual Congress, Milan 2023. Arnhem, The Netherlands.
https://uroweb.org/guidelines/urological-infections
50.Palou, J., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate. Eur Urol, 2013. 63: 81.
https://pubmed.ncbi.nlm.nih.gov/22938869/
51.Roupret, M., et al. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma In: EAU Guidelines published at the 38th EAU Annual Congress, Milan 2023. Arnhem, The Netherlands.
https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma
52.Roehrborn, C.G., et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology, 2001. 58: 642.
https://pubmed.ncbi.nlm.nih.gov/11711329/
53.Abrams, P., et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol, 2013. 189: S93.
https://pubmed.ncbi.nlm.nih.gov/23234640/
54.Medicine., E.C.o.L. European urinalysis guidelines. Scand J Clin Lab Invest Suppl, 2000. 231: 1.
https://pubmed.ncbi.nlm.nih.gov/12647764/
55.Khasriya, R., et al. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol, 2010. 183: 1843.
https://pubmed.ncbi.nlm.nih.gov/20303096/
56.Roehrborn, C.G., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology, 1999. 53: 581.
https://pubmed.ncbi.nlm.nih.gov/10096388/
57.Bohnen, A.M., et al. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol, 2007. 51: 1645.
https://pubmed.ncbi.nlm.nih.gov/17320271/
58.Kayikci, A., et al. Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms. Urology, 2012. 80: 1088.
https://pubmed.ncbi.nlm.nih.gov/23107399/
59.Morote, J., et al. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol, 2000. 38: 91.
https://pubmed.ncbi.nlm.nih.gov/10859448/
60.Mottet, N., et al. EAU - EANM - ESTRO - ESUR - ISUP – SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan. 2021.
https://uroweb.org/guidelines/archive/prostate-cancer
61.Roehrborn, C.G., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
J Urol, 2000. 163: 13.
https://pubmed.ncbi.nlm.nih.gov/10604304/
62.Roehrborn, C.G., et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 1999. 54: 662.
https://pubmed.ncbi.nlm.nih.gov/10510925/
63.Djavan, B., et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology, 2004. 64: 1144.
https://pubmed.ncbi.nlm.nih.gov/15596187/
64.Patel, D.N., et al. PSA predicts development of incident lower urinary tract symptoms: Results from the REDUCE study. Prostate Cancer Prostatic Dis, 2018. 21: 238.
https://pubmed.ncbi.nlm.nih.gov/29795141/
65.McConnell, J.D., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003. 349: 2387.
https://pubmed.ncbi.nlm.nih.gov/14681504/
66.Roehrborn, C.G. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int, 2006. 97: 734.
https://pubmed.ncbi.nlm.nih.gov/16536764/
67.Jacobsen, S.J., et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol, 1999. 162: 1301.
https://pubmed.ncbi.nlm.nih.gov/10492184/
68.Lim, K.B., et al. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol, 2006. 13: 1509.
https://pubmed.ncbi.nlm.nih.gov/17118026/
69.Meigs, J.B., et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol, 2001. 54: 935.
https://pubmed.ncbi.nlm.nih.gov/11520654/
70.Gerber, G.S., et al. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology, 1997. 49: 697.
https://pubmed.ncbi.nlm.nih.gov/9145973/
71.Oelke, M., et al. Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. Neurourol Urodyn, 2012. 31: 322.
https://pubmed.ncbi.nlm.nih.gov/22415947/
72.Comiter, C.V., et al. Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J Urol, 1997. 158: 181.
https://pubmed.ncbi.nlm.nih.gov/9186351/
73.Koch, W.F., et al. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol, 1996. 155: 186.
https://pubmed.ncbi.nlm.nih.gov/7490828/
74.Rule, A.D., et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int, 2005. 67: 2376.
https://pubmed.ncbi.nlm.nih.gov/15882282/
75.Hong, S.K., et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2010. 105: 1424.
https://pubmed.ncbi.nlm.nih.gov/19874305/
76.Lee, J.H., et al. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. Urology, 2013. 82: 1381.
https://pubmed.ncbi.nlm.nih.gov/24063940/
77.Mebust, W.K., et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol, 1989. 141: 243.
https://pubmed.ncbi.nlm.nih.gov/2643719/
78.Rule, A.D., et al. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol, 2005. 174: 1317.
https://pubmed.ncbi.nlm.nih.gov/16145411/
79.Sullivan, M.P., et al. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol, 1996. 155: 1995.
https://pubmed.ncbi.nlm.nih.gov/8618307/
80.Oelke, M., et al. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol, 2007. 52: 827.
https://pubmed.ncbi.nlm.nih.gov/17207910/
81.Emberton, M. Definition of at-risk patients: dynamic variables. BJU Int, 2006. 97 Suppl 2: 12.
https://pubmed.ncbi.nlm.nih.gov/16507047/
82.Mochtar, C.A., et al. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol, 2006. 175: 213.
https://pubmed.ncbi.nlm.nih.gov/16406914/
83.Jorgensen, J.B., et al. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol, 1992. 69: 265.
https://pubmed.ncbi.nlm.nih.gov/1373664/
84.Kranse, R., et al. Causes for variability in repeated pressure-flow measurements. Urology, 2003. 61: 930.
https://pubmed.ncbi.nlm.nih.gov/12736007/
85.Reynard, J.M., et al. The ICS-’BPH’ Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol, 1998. 82: 619.
https://pubmed.ncbi.nlm.nih.gov/9839573/
86.Idzenga, T., et al. Accuracy of maximum flow rate for diagnosing bladder outlet obstruction can be estimated from the ICS nomogram. Neurourol Urodyn, 2008. 27: 97.
https://pubmed.ncbi.nlm.nih.gov/17600368/
87.Siroky, M.B., et al. The flow rate nomogram: I. Development. J Urol, 1979. 122: 665.
https://pubmed.ncbi.nlm.nih.gov/159366/
88.Siroky, M.B., et al. The flow rate nomogram: II. Clinical correlation. J Urol, 1980. 123: 208.
https://pubmed.ncbi.nlm.nih.gov/7354519/
89.Reynard, J.M., et al. The value of multiple free-flow studies in men with lower urinary tract symptoms. Br J Urol, 1996. 77: 813.
https://pubmed.ncbi.nlm.nih.gov/8705213/
90.Grossfeld, G.D., et al. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am, 2000. 38: 31.
https://pubmed.ncbi.nlm.nih.gov/10664665/
91.Thorpe, A., et al. Benign prostatic hyperplasia. Lancet, 2003. 361: 1359.
https://pubmed.ncbi.nlm.nih.gov/12711484/
92.Wilkinson, A.G., et al. Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism? Br J Urol, 1992. 70: 53.
https://pubmed.ncbi.nlm.nih.gov/1379105/
93.Loch, A.C., et al. Technical and anatomical essentials for transrectal ultrasound of the prostate. World J Urol, 2007. 25: 361.
https://pubmed.ncbi.nlm.nih.gov/17701043/
94.Stravodimos, K.G., et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol, 2009. 41: 767.
https://pubmed.ncbi.nlm.nih.gov/19350408/
95.Shoukry, I., et al. Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. Br J Urol, 1975. 47: 559.
https://pubmed.ncbi.nlm.nih.gov/1191927/
96.Anikwe, R.M. Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. Int Surg, 1976. 61: 392.
https://pubmed.ncbi.nlm.nih.gov/61184/
97.el Din, K.E., et al. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol, 1996. 156: 1020.
https://pubmed.ncbi.nlm.nih.gov/8709300/
98.Oelke, M., et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol, 2008. 54: 419.
https://pubmed.ncbi.nlm.nih.gov/18325657/
99.Oh, M.M., et al. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? Urology, 2011. 77: 167.
https://pubmed.ncbi.nlm.nih.gov/20934743/
100.Jeong, S.J., et al. Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women. Korean J Urol, 2012. 53: 342.
https://pubmed.ncbi.nlm.nih.gov/22670194/
101.Thomas, A.W., et al. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int, 2004. 93: 745.
https://pubmed.ncbi.nlm.nih.gov/15049984/
102.Al-Hayek, S., et al. Natural history of detrusor contractility--minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. Scand J Urol Nephrol Suppl,
2004: 101.
https://pubmed.ncbi.nlm.nih.gov/15545204/
103.Thomas, A.W., et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol, 2005. 174: 1887.
https://pubmed.ncbi.nlm.nih.gov/16217330/
104.Drake, M.J., et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol, 2020. 78: 701.
https://pubmed.ncbi.nlm.nih.gov/32616406/
105.Aiello, M., et al. Quality control of uroflowmetry and urodynamic data from two large multicenter studies of male lower urinary tract symptoms. Neurourol Urodyn, 2020. 39: 1170.
https://pubmed.ncbi.nlm.nih.gov/32187720/
106.Young, G.J., et al. Prostate Surgery for Men with Lower Urinary Tract Symptoms: Do We Need Urodynamics to Find the Right Candidates? Exploratory Findings from the UPSTREAM Trial. Eur Urol Focus, 2021.
https://pubmed.ncbi.nlm.nih.gov/34922898/
107.Blok, B., et al. EAU Guidelines on Neuro-urology In: EAU Guidelines published at the 38th EAU Annual Congress, Milan 2023. Arnhem, The Netherlands.
https://uroweb.org/guidelines/neuro-urology
108.Kojima, M., et al. Correlation of presumed circle area ratio with infravesical obstruction in men with lower urinary tract symptoms. Urology, 1997. 50: 548.
https://pubmed.ncbi.nlm.nih.gov/9338730/
109.Chia, S.J., et al. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int, 2003. 91: 371.
https://pubmed.ncbi.nlm.nih.gov/12603417/
110.Keqin, Z., et al. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology, 2007. 70: 1096.
https://pubmed.ncbi.nlm.nih.gov/18158025/
111.Mariappan, P., et al. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol, 2007. 178: 573.
https://pubmed.ncbi.nlm.nih.gov/17570437/
112.Tan, Y.H., et al. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol, 2003. 170: 2339.
https://pubmed.ncbi.nlm.nih.gov/14634410/
113.Arnolds, M., et al. Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstruction. Curr Opin Urol, 2009. 19: 55.
https://pubmed.ncbi.nlm.nih.gov/19057217/
114.Manieri, C., et al. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J Urol, 1998. 159: 761.
https://pubmed.ncbi.nlm.nih.gov/9474143/
115.Kessler, T.M., et al. Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study? J Urol, 2006. 175: 2170.
https://pubmed.ncbi.nlm.nih.gov/16697831/
116.Blatt, A.H., et al. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J Urol, 2008. 179: 2275.
https://pubmed.ncbi.nlm.nih.gov/18423703/
117.Oelke, M. International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. Neurourol Urodyn, 2010. 29: 634.
https://pubmed.ncbi.nlm.nih.gov/20432327/
118.Kojima, M., et al. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology, 1996. 47: 942.
https://pubmed.ncbi.nlm.nih.gov/8677600/
119.Kojima, M., et al. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol, 1997. 157: 476.
https://pubmed.ncbi.nlm.nih.gov/8996337/
120.Akino, H., et al. Ultrasound-estimated bladder weight predicts risk of surgery for benign prostatic hyperplasia in men using alpha-adrenoceptor blocker for LUTS. Urology, 2008. 72: 817.
https://pubmed.ncbi.nlm.nih.gov/18597835/
121.McIntosh, S.L., et al. Noninvasive assessment of bladder contractility in men. J Urol, 2004. 172: 1394.
https://pubmed.ncbi.nlm.nih.gov/15371853/
122.Drinnan, M.J., et al. Inter-observer agreement in the estimation of bladder pressure using a penile cuff. Neurourol Urodyn, 2003. 22: 296.
https://pubmed.ncbi.nlm.nih.gov/12808703/
123.Griffiths, C.J., et al. A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol, 2005. 174: 1323.
https://pubmed.ncbi.nlm.nih.gov/16145412/
124.Clarkson, B., et al. Continuous non-invasive measurement of bladder voiding pressure using an experimental constant low-flow test. Neurourol Urodyn, 2012. 31: 557.
https://pubmed.ncbi.nlm.nih.gov/22190105/
125.Van Mastrigt, R., et al. Towards a noninvasive urodynamic diagnosis of infravesical obstruction. BJU Int, 1999. 84: 195.
https://pubmed.ncbi.nlm.nih.gov/10444152/
126.Pel, J.J., et al. Development of a non-invasive strategy to classify bladder outlet obstruction in male patients with LUTS. Neurourol Urodyn, 2002. 21: 117.
https://pubmed.ncbi.nlm.nih.gov/11857664/
127.Shinbo, H., et al. Application of ultrasonography and the resistive index for evaluating bladder outlet obstruction in patients with benign prostatic hyperplasia. Curr Urol Rep, 2011. 12: 255.
https://pubmed.ncbi.nlm.nih.gov/21475953/
128.Ku, J.H., et al. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms. Urology, 2010. 75: 1467.
https://pubmed.ncbi.nlm.nih.gov/19962734/
129.Malde, S., et al. Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. Eur Urol, 2016.
https://pubmed.ncbi.nlm.nih.gov/27687821/
130.Els, M., et al. Prospective comparison of the novel visual prostate symptom score (VPSS) versus the international prostate symptom score (IPSS), and assessment of patient pain perception with regard to transrectal ultrasound guided prostate biopsy. Int Braz J Urol, 2019. 45: 137.
https://pubmed.ncbi.nlm.nih.gov/30620160/
131.Sanman, K.N., et al. Can new, improvised Visual Prostate Symptom Score replace the International Prostate Symptom Score? Indian perspective. Indian J Urol, 2020. 36: 123.
https://pubmed.ncbi.nlm.nih.gov/32549664/
132.Grosso, G., et al. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus, 2019. 5: 497.
https://pubmed.ncbi.nlm.nih.gov/29398458/
133.Ball, A.J., et al. The natural history of untreated “prostatism”. Br J Urol, 1981. 53: 613.
https://pubmed.ncbi.nlm.nih.gov/6172172/
134.Kirby, R.S. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology, 2000. 56: 3.
https://pubmed.ncbi.nlm.nih.gov/11074195/
135.Isaacs, J.T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl, 1990. 3: 1.
https://pubmed.ncbi.nlm.nih.gov/1689166/
136.Netto, N.R., Jr., et al. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology, 1999. 53: 314.
https://pubmed.ncbi.nlm.nih.gov/9933046/
137.Flanigan, R.C., et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol, 1998. 160: 12.
https://pubmed.ncbi.nlm.nih.gov/9628595/
138.Wasson, J.H., et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med, 1995. 332: 75.
https://pubmed.ncbi.nlm.nih.gov/7527493/
139.Brown, C.T., et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ, 2007. 334: 25.
https://pubmed.ncbi.nlm.nih.gov/17118949/
140.Yap, T.L., et al. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int, 2009. 104: 1104.
https://pubmed.ncbi.nlm.nih.gov/19485993/
141.Albarqouni, L., et al. Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis. Ann Fam Med, 2021. 19: 157.
https://pubmed.ncbi.nlm.nih.gov/33685877/
142.Brown, C.T., et al. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol, 2004. 46: 254.
https://pubmed.ncbi.nlm.nih.gov/15245822/
143.Michel, M.C., et al. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 2006. 147 Suppl 2: S88.
https://pubmed.ncbi.nlm.nih.gov/16465187/
144.Kortmann, B.B., et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology, 2003. 62: 1.
https://pubmed.ncbi.nlm.nih.gov/12837408/
145.Barendrecht, M.M., et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn, 2008. 27: 226.
https://pubmed.ncbi.nlm.nih.gov/17638312/
146.Djavan, B., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology, 2004. 64: 1081.
https://pubmed.ncbi.nlm.nih.gov/15596173/
147.Michel, M.C., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis, 1998. 1: 332.
https://pubmed.ncbi.nlm.nih.gov/12496876/
148.Fusco, F., et al. alpha1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol, 2016. 69: 1091.
https://pubmed.ncbi.nlm.nih.gov/26831507/
149.Boyle, P., et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology, 2001. 58: 717.
https://pubmed.ncbi.nlm.nih.gov/11711348/
150.Roehrborn, C.G. Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis, 2006. 9: 121.
https://pubmed.ncbi.nlm.nih.gov/16304557/
151.Roehrborn, C.G., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol, 2008. 179: 616.
https://pubmed.ncbi.nlm.nih.gov/18082216/
152.Roehrborn, C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010. 57: 123.
https://pubmed.ncbi.nlm.nih.gov/19825505/
153.Creta, M., et al. Detrusor overactivity and underactivity: implication for lower urinary tract symptoms related to benign prostate hyperplasia diagnosis and treatment. Minerva Urol Nephrol, 2020.
https://pubmed.ncbi.nlm.nih.gov/32026666/
154.Karavitakis, M., et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol, 2019. 75: 788.
https://pubmed.ncbi.nlm.nih.gov/30773327/
155.Nickel, J.C., et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract, 2008.
62: 1547.
https://pubmed.ncbi.nlm.nih.gov/18822025/
156.Barendrecht, M.M., et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int, 2005. 95 Suppl 4: 19.
https://pubmed.ncbi.nlm.nih.gov/15871732/
157.Chapple, C.R., et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol, 2011. 59: 342.
https://pubmed.ncbi.nlm.nih.gov/21109344/
158.Welk, B., et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ, 2015. 351: h5398.
https://pubmed.ncbi.nlm.nih.gov/26502947/
159.Chang, D.F., et al. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg, 2005. 31: 664.
https://pubmed.ncbi.nlm.nih.gov/15899440/
160.Chatziralli, I.P., et al. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology, 2011. 118: 730.
https://pubmed.ncbi.nlm.nih.gov/21168223/
161.van Dijk, M.M., et al. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs, 2006. 66: 287.
https://pubmed.ncbi.nlm.nih.gov/16526818/
162.Gacci, M., et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med, 2014. 11: 1554.
https://pubmed.ncbi.nlm.nih.gov/24708055/
163.Andriole, G., et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol, 2004. 172: 1399.
https://pubmed.ncbi.nlm.nih.gov/15371854/
164.Rittmaster, R.S., et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab, 1996. 81: 814.
https://pubmed.ncbi.nlm.nih.gov/8636309/
165.Naslund, M.J., et al. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther, 2007. 29: 17.
https://pubmed.ncbi.nlm.nih.gov/17379044/
166.Andersen, J.T., et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology, 1995. 46: 631.
https://pubmed.ncbi.nlm.nih.gov/7495111/
167.Kirby, R.S., et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 2003. 61: 119.
https://pubmed.ncbi.nlm.nih.gov/12559281/
168.Lepor, H., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med, 1996. 335: 533.
https://pubmed.ncbi.nlm.nih.gov/8684407/
169.Marberger, M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology, 1998. 51: 677.
https://pubmed.ncbi.nlm.nih.gov/9610579/
170.McConnell, J.D., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 1998. 338: 557.
https://pubmed.ncbi.nlm.nih.gov/9475762/
171.Nickel, J.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Cmaj, 1996. 155: 1251.
https://pubmed.ncbi.nlm.nih.gov/8911291/
172.Roehrborn, C.G., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002. 60: 434.
https://pubmed.ncbi.nlm.nih.gov/12350480/
173.Nickel, J.C., et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int, 2011. 108: 388.
https://pubmed.ncbi.nlm.nih.gov/21631695/
174.Boyle, P., et al. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 1996. 48: 398.
https://pubmed.ncbi.nlm.nih.gov/8804493/
175.Gittelman, M., et al. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol, 2006. 176: 1045.
https://pubmed.ncbi.nlm.nih.gov/16890688/
176.Roehrborn, C.G., et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int, 2005. 96: 572.
https://pubmed.ncbi.nlm.nih.gov/16104912/
177.Roehrborn, C.G., et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol, 2009. 55: 461.
https://pubmed.ncbi.nlm.nih.gov/19013011/
178.Roehrborn, C.G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int, 2008. 101 Suppl 3: 17.
https://pubmed.ncbi.nlm.nih.gov/18307681/
179.Andersen, J.T., et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology, 1997. 49: 839.
https://pubmed.ncbi.nlm.nih.gov/9187688/
180.Kirby, R.S., et al. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. Eur Urol, 1993. 24: 20.
https://pubmed.ncbi.nlm.nih.gov/7689971/
181.Tammela, T.L., et al. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol, 1995. 154: 1466.
https://pubmed.ncbi.nlm.nih.gov/7544845/
182.Donohue, J.F., et al. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol, 2002. 168: 2024.
https://pubmed.ncbi.nlm.nih.gov/12394700/
183.Khwaja, M.A., et al. The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity. J Coll Phys Surg Pakistan, 2016. 26: 213.
https://pubmed.ncbi.nlm.nih.gov/26975954/
184.Corona, G., et al. Sexual dysfunction in subjects treated with inhibitors of 5alpha-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology, 2017. 5: 671.
https://pubmed.ncbi.nlm.nih.gov/28453908/
185.Andriole, G.L., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med, 2010. 362: 1192.
https://pubmed.ncbi.nlm.nih.gov/20357281/
186.Thompson, I.M., et al. The influence of finasteride on the development of prostate cancer. N Engl
J Med, 2003. 349: 215.
https://pubmed.ncbi.nlm.nih.gov/12824459/
187.Hsieh, T.F., et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One, 2015. 10: e0119694.
https://pubmed.ncbi.nlm.nih.gov/25803433/
188.Skeldon, S.C., et al. The Cardiovascular Safety of Dutasteride. J Urol, 2017. 197: 1309.
https://pubmed.ncbi.nlm.nih.gov/27866006/
189.Wei, L., et al. Incidence of type 2 diabetes mellitus in men receiving steroid 5alpha-reductase inhibitors: Population based cohort study. BMJ (Online), 2019. 365: l1204.
https://pubmed.ncbi.nlm.nih.gov/30971393/
190.Chess-Williams, R., et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol, 2001. 21: 243.
https://pubmed.ncbi.nlm.nih.gov/12123469/
191.Matsui, M., et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A, 2000. 97: 9579.
https://pubmed.ncbi.nlm.nih.gov/10944224/
192.Kono, M., et al. Central muscarinic receptor subtypes regulating voiding in rats. J Urol, 2006. 175: 353.
https://pubmed.ncbi.nlm.nih.gov/16406941/
193.Wuest, M., et al. Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. Naunyn Schmiedebergs Arch Pharmacol, 2005. 372: 203.
https://pubmed.ncbi.nlm.nih.gov/16283254/
194.Goldfischer, E.R., et al. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study. Neurourol Urodyn, 2015. 34: 37.
https://pubmed.ncbi.nlm.nih.gov/24133005/
195.Baldwin, C.M., et al. Transdermal oxybutynin. Drugs, 2009. 69: 327.
https://pubmed.ncbi.nlm.nih.gov/19275276/
196.Chapple, C.R., et al. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol, 2006. 49: 651.
https://pubmed.ncbi.nlm.nih.gov/16530611/
197.Michel, M.C., et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol, 2002. 168: 1027.
https://pubmed.ncbi.nlm.nih.gov/12187215/
198.Chapple, C., et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin, 2015. 31: 1201.
https://pubmed.ncbi.nlm.nih.gov/25798911/
199.Dmochowski, R., et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol, 2007. 51: 1054.
https://pubmed.ncbi.nlm.nih.gov/17097217/
200.Herschorn, S., et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology, 2010. 75: 1149.
https://pubmed.ncbi.nlm.nih.gov/19914702/
201.Hofner, K., et al. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol, 2007. 25: 627.
https://pubmed.ncbi.nlm.nih.gov/17906864/
202.Roehrborn, C.G., et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int, 2006. 97: 1003.
https://pubmed.ncbi.nlm.nih.gov/16643482/
203.Kaplan, S.A., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Jama, 2006. 296: 2319.
https://pubmed.ncbi.nlm.nih.gov/17105794/
204.Kaplan, S.A., et al. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 2005. 174: 2273.
https://pubmed.ncbi.nlm.nih.gov/16280803/
205.Kaplan, S.A., et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male, 2010. 13: 100.
https://pubmed.ncbi.nlm.nih.gov/20001469/
206.Gacci, M., et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep, 2015. 16: 60.
https://pubmed.ncbi.nlm.nih.gov/26149965/
207.Roehrborn, C.G., et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology, 2008. 72: 1061.
https://pubmed.ncbi.nlm.nih.gov/18817961/
208.Yokoyama, T., et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol, 2009. 43: 307.
https://pubmed.ncbi.nlm.nih.gov/19396723/
209.Abrams, P., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol, 2006. 175: 999.
https://pubmed.ncbi.nlm.nih.gov/16469601/
210.Andersson, K.E. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in the Bladder. Int Neurourol J, 2017. 21: 6.
https://pubmed.ncbi.nlm.nih.gov/28361520/
211.Chapple, C.R., et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013. 63: 296.
https://pubmed.ncbi.nlm.nih.gov/23195283/
212.Herschorn, S., et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013. 82: 313.
https://pubmed.ncbi.nlm.nih.gov/23769122/
213.Khullar, V., et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol, 2013. 63: 283.
https://pubmed.ncbi.nlm.nih.gov/23182126/
214.Nitti, V.W., et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol, 2013. 189: 1388.
https://pubmed.ncbi.nlm.nih.gov/23079373/
215.Yamaguchi, O., et al. Efficacy and Safety of the Selective beta3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Low Urin Tract Symptoms, 2015. 7: 84.
https://pubmed.ncbi.nlm.nih.gov/26663687/
216.Sebastianelli, A., et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol, 2018. 25: 196.
https://pubmed.ncbi.nlm.nih.gov/29205506/
217.Liao, C.H., et al. Mirabegron 25mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Urology, 2018. 117: 115.
https://pubmed.ncbi.nlm.nih.gov/29630956/
218.Drake, M.J., et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol, 2016. 70: 136.
https://pubmed.ncbi.nlm.nih.gov/26965560/
219.Kuo, H.C., et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn, 2015. 34: 685.
https://pubmed.ncbi.nlm.nih.gov/25130281/
220.Abrams, P., et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World
J Urol, 2017. 35: 827.
https://pubmed.ncbi.nlm.nih.gov/27514371/
221.Khullar, V., et al. Patient-reported outcomes with the beta3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn, 2016. 35: 987.
https://pubmed.ncbi.nlm.nih.gov/26288118/
222.Yamaguchi, O., et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int, 2015. 116: 612.
https://pubmed.ncbi.nlm.nih.gov/25639296/
223.White, W.B., et al. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertension, 2018. 12: 768.
https://pubmed.ncbi.nlm.nih.gov/30181042/
224.Nitti, V.W., et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol, 2013. 190: 1320.
https://pubmed.ncbi.nlm.nih.gov/23727415/
225.Lee, Y.K., et al. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int, 2018. 18: 1330.
https://pubmed.ncbi.nlm.nih.gov/29931793/
226.Wagg, A., et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin, 2016. 32: 621.
https://pubmed.ncbi.nlm.nih.gov/26828974/
227.Wagg, A., et al. Efficacy, safety, and tolerability of mirabegron in patients aged >=65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol, 2020. 77: 211.
https://pubmed.ncbi.nlm.nih.gov/31733990/
228.Herschorn, S., et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int, 2017. 120: 562.
https://pubmed.ncbi.nlm.nih.gov/28418102/
229.Chapple, C.R., et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol, 2017. 72: 389.
https://pubmed.ncbi.nlm.nih.gov/28196724/
230.Staskin, D., et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol, 2020. 204: 316.
https://pubmed.ncbi.nlm.nih.gov/32068484/
231.Giuliano, F., et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol, 2013. 63: 506.
https://pubmed.ncbi.nlm.nih.gov/23018163/
232.Morelli, A., et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med, 2011. 8: 2746.
https://pubmed.ncbi.nlm.nih.gov/21812935/
233.Vignozzi, L., et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate, 2013. 73: 1391.
https://pubmed.ncbi.nlm.nih.gov/23765639/
234.Nagasubramanian, S., et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int, 2020. 125: 718.
https://pubmed.ncbi.nlm.nih.gov/32012409/
235.Pattanaik, S., et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev, 2018. 2018: CD010060.
https://pubmed.ncbi.nlm.nih.gov/30480763/
236.Guo, B., et al. Comparative effectiveness of tadalafil versus tamsulosin in treating lower urinary tract symptoms suggestive of benign prostate hyperplasia: A meta-analysis of randomized controlled trials. Med Sci Monitor, 2020. 26: e923179.
https://pubmed.ncbi.nlm.nih.gov/32327621/
237.Gacci, M., et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012. 61: 994.
https://pubmed.ncbi.nlm.nih.gov/22405510/
238.Wang, Y., et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms, 2018. 10: 84.
https://pubmed.ncbi.nlm.nih.gov/29341503/
239.Oelke, M., et al. Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol, 2015. 193: 1581.
https://pubmed.ncbi.nlm.nih.gov/25437533/
240.Donatucci, C.F., et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int, 2011. 107: 1110.
https://pubmed.ncbi.nlm.nih.gov/21244606/
241.Porst, H., et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology, 2013. 82: 667.
https://pubmed.ncbi.nlm.nih.gov/23876588/
242.Brock, G.B., et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol, 2014. 191: 405.
https://pubmed.ncbi.nlm.nih.gov/24096120/
243.Roehrborn, C.G., et al. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol, 2014. 191: 1045.
https://pubmed.ncbi.nlm.nih.gov/24445278/
244.Oelke, M., et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged >=75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int, 2017. 119: 793.
https://pubmed.ncbi.nlm.nih.gov/27988986/
245.Buck, A.C. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol, 2004. 172: 1792.
https://pubmed.ncbi.nlm.nih.gov/15540722/
246.Dmochowski, R., et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol, 2013. 189: S135.
https://pubmed.ncbi.nlm.nih.gov/23234619/
247.Chen, P.-C., et al. Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis. Urol Sci, 2020. 31: 99.
https://www.e-urol-sci.com/article.asp?issn=1879-5226;year=2020;volume=31;issue=3;spage=99;epage=107;aulast=Chen
248.Casabe, A., et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol, 2014. 191: 727.
https://pubmed.ncbi.nlm.nih.gov/24096118/
249.EMA, Tadalafil Lilly : EPAR - Product Information, European Medicines Agency, Editor. 2017.
https://www.ema.europa.eu/en/medicines/human/EPAR/tadalafil-lilly
250.Salonia, A.B., et al. European Association of Urology Guidelines on Sexual and Reproductive Health. In: EAU Guidelines published at the 38th EAU Annual Congress, Milan 2023. Arnhem, The Netherlands.
https://uroweb.org/guidelines/sexual-and-reproductive-health
251.Madersbacher, S., et al. Plant extracts: sense or nonsense? Curr Opin Urol, 2008. 18: 16.
https://pubmed.ncbi.nlm.nih.gov/18090484/
252.Levin, R.M., et al. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res, 2000. 28: 201.
https://pubmed.ncbi.nlm.nih.gov/10929430/
253.Habib, F.K., et al. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis, 2004. 7: 195.
https://pubmed.ncbi.nlm.nih.gov/15289814/
254.Scaglione, F., et al. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology, 2008. 82: 270.
https://pubmed.ncbi.nlm.nih.gov/18849646/
255.De Monte, C., et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol, 2014. 14: 63.
https://pubmed.ncbi.nlm.nih.gov/25112532/
256.EMA. European Union monographs for Herbal Medicinal Products.
https://pubmed.ncbi.nlm.nih.gov/
257.Committee on Herbal Medicinal Products. European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015.
258.Committee on Herbal Medicinal Products. Community herbal monograph on Cucurbita pepo L., semen. EMA/HMPC/136024/2010, 2012.
259.Committee on Herbal Medicinal Products. European Union herbal monograph on Prunus africana (Hook f.) Kalkm., cortex. EMA/HMPC/680626/2013, 2016.
260.Committee on Herbal Medicinal Products. Community herbal monograph on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix. EMA/HMPC/461160/2008, 2012.
261.Committee on Herbal Medicinal Products. European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba EMA/HMPC/712511/2014, 2015.
262.Tacklind, J., et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev, 2009: CD001423.
https://pubmed.ncbi.nlm.nih.gov/19370565/
263.Novara, G., et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2016. 2: 553.
https://pubmed.ncbi.nlm.nih.gov/28723522/
264.Vela-Navarrete, R., et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R)) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int, 2018. 122: 1049.
https://pubmed.ncbi.nlm.nih.gov/29694707/
265.Russo, G.I., et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/31952967/
266.Boeri, L., et al. Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone. Sci Rep, 2017. 7: 15179.
https://pubmed.ncbi.nlm.nih.gov/29123161/
267.Debruyne, F.M., et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol, 1998. 34: 169.
https://pubmed.ncbi.nlm.nih.gov/9732187/
268.Barkin, J., et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol, 2003. 44: 461.
https://pubmed.ncbi.nlm.nih.gov/14499682/
269.Nickel, J.C., et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J, 2008. 2: 16.
https://pubmed.ncbi.nlm.nih.gov/18542722/
270.Athanasopoulos, A., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol, 2003. 169: 2253.
https://pubmed.ncbi.nlm.nih.gov/12771763/
271.Roehrborn, C.G., et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart((R)) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int, 2015. 116: 450.
https://pubmed.ncbi.nlm.nih.gov/25565364/
272.Roehrborn, C.G., et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int, 2014. 113: 623.
https://pubmed.ncbi.nlm.nih.gov/24127818/
273.Kaplan, S.A., et al. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
J Urol, 2016. 195: 1825.
https://pubmed.ncbi.nlm.nih.gov/26678956/
274.Chapple, C., et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol, 2009. 56: 534.
https://pubmed.ncbi.nlm.nih.gov/19070418/
275.Kaplan, S.A., et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol, 2009. 182: 2825.
https://pubmed.ncbi.nlm.nih.gov/19837435/
276.Lee, J.Y., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int, 2004. 94: 817.
https://pubmed.ncbi.nlm.nih.gov/15476515/
277.Lee, K.S., et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol, 2005. 174: 1334.
https://pubmed.ncbi.nlm.nih.gov/16145414/
278.MacDiarmid, S.A., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc, 2008. 83: 1002.
https://pubmed.ncbi.nlm.nih.gov/18775200/
279.Saito, H., et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride (Harnal capsules) alone and in combination with propiverine hydrochloride (BUP-4 tablets) in patients with prostatic hypertrophy associated with pollakisuria and/or urinary incontinence. Jpn J Urol Surg, 1999. 12: 525.
http://www.eurostaga.com/pdf_estudios/lostam/lostam_en_seguridad_en_HPB.pdf
280.Yang, Y., et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl), 2007. 120: 370.
https://pubmed.ncbi.nlm.nih.gov/17376305/
281.van Kerrebroeck, P., et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol, 2013. 64: 1003.
https://pubmed.ncbi.nlm.nih.gov/23932438/
282.Maruyama, O., et al. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. Int J Urol, 2006. 13: 1280.
https://pubmed.ncbi.nlm.nih.gov/17010005/
283.Lee, H.N., et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract, 2015. 69: 444.
https://pubmed.ncbi.nlm.nih.gov/25363606/
284.Kaplan, S.A., et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int, 2012. 109: 1831.
https://pubmed.ncbi.nlm.nih.gov/21966995/
285.Kim, T.H., et al. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an alpha-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial. BJU Int, 2016. 117: 307.
https://pubmed.ncbi.nlm.nih.gov/26305143/
286.Athanasopoulos, A., et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol, 2011. 60: 94.
https://pubmed.ncbi.nlm.nih.gov/21497434/
287.Kaplan, S.A., et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract, 2011. 65: 487.
https://pubmed.ncbi.nlm.nih.gov/21210910/
288.Kim, H.J., et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One, 2017. 12: e0169248.
https://pubmed.ncbi.nlm.nih.gov/28072862/
289.Van Kerrebroeck, P., et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol, 2013. 64: 398.
https://pubmed.ncbi.nlm.nih.gov/23537687/
290.Drake, M.J., et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol, 2015. 67: 262.
https://pubmed.ncbi.nlm.nih.gov/25070148/
291.Drake, M.J., et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin OCAS: results from the NEPTUNE study. BJU Int, 2015.
https://pubmed.ncbi.nlm.nih.gov/25907003/
292.Rees, J., et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn, 2019. 38: 981.
https://pubmed.ncbi.nlm.nih.gov/30801782/
293.Burgio, K.L., et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Int Med, 2020. 180: 411.
https://pubmed.ncbi.nlm.nih.gov/31930360/
294.Drake, M.J., et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One, 2017.
12: e0170726.
https://pubmed.ncbi.nlm.nih.gov/28166296/
295.Gong, M., et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin, 2015. 31: 1781.
https://pubmed.ncbi.nlm.nih.gov/26211817/
296.Kaplan, S.A., et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol, 2013. 63: 158.
https://pubmed.ncbi.nlm.nih.gov/22831853/
297.Kakizaki, H., et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus, 2020. 6: 729.
https://pubmed.ncbi.nlm.nih.gov/31718957/
298.Kaplan, S.A., et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol, 2020. 203: 1163.
https://pubmed.ncbi.nlm.nih.gov/31895002/
299.Ichihara, K., et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol, 2015. 193: 921.
https://pubmed.ncbi.nlm.nih.gov/25254938/
300.Van Gelderen, M., et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. Int J Clin Pharmacol Ther, 2014. 52: 693.
https://pubmed.ncbi.nlm.nih.gov/24755125/
301.Soliman, M.G., et al. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol, 2020. 39: 2049.
https://pubmed.ncbi.nlm.nih.gov/32869151/
302.Speakman, M.J., et al. What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction? Eur Urol Focus, 2019. 5: 351.
https://pubmed.ncbi.nlm.nih.gov/31204291/
303.Issa, M.M. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol, 2008. 22: 1587.
https://pubmed.ncbi.nlm.nih.gov/18721041/
304.Rassweiler, J., et al. Bipolar transurethral resection of the prostate--technical modifications and early clinical experience. Minim Invasive Ther Allied Technol, 2007. 16: 11.
https://pubmed.ncbi.nlm.nih.gov/17365673/
305.Cornu, J.N., et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol, 2015. 67: 1066.
https://pubmed.ncbi.nlm.nih.gov/24972732/
306.Reich, O., et al. Techniques and long-term results of surgical procedures for BPH. Eur Urol, 2006. 49: 970.
https://pubmed.ncbi.nlm.nih.gov/16481092/
307.Madersbacher, S., et al. Is transurethral resection of the prostate still justified? BJU Int, 1999. 83: 227.
https://pubmed.ncbi.nlm.nih.gov/10233485/
308.Madersbacher, S., et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol, 2005. 47: 499.
https://pubmed.ncbi.nlm.nih.gov/15774249/
309.Eredics, K., et al. Reoperation Rates and Mortality After Transurethral and Open Prostatectomy in a Long-term Nationwide Analysis: Have We Improved Over a Decade? Urology, 2018. 118: 152.
https://pubmed.ncbi.nlm.nih.gov/29733869/
310.Alexander, C.E., et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev, 2019. 2019: CD009629.
https://pubmed.ncbi.nlm.nih.gov/31792928/
311.Mamoulakis, C., et al. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol, 2009. 56: 798.
https://pubmed.ncbi.nlm.nih.gov/19595501/
312.Burke, N., et al. Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology, 2010. 75: 1015.
https://pubmed.ncbi.nlm.nih.gov/19854492/
313.Omar, M.I., et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int, 2014. 113: 24.
https://pubmed.ncbi.nlm.nih.gov/24053602/
314.Inzunza, G., et al. Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? Medwave, 2018. 18: e7134.
https://pubmed.ncbi.nlm.nih.gov/29351269/
315.Treharne, C., et al. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. Eur Urol focus, 2016. 4: 270.
https://pubmed.ncbi.nlm.nih.gov/28753756/
316.Autorino, R., et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol, 2009. 55: 922.
https://pubmed.ncbi.nlm.nih.gov/19185975/
317.Chen, Q., et al. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. BJU Int, 2010. 106: 1339.
https://pubmed.ncbi.nlm.nih.gov/20477825/
318.Fagerstrom, T., et al. Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. J Endourol, 2011. 25: 1043.
https://pubmed.ncbi.nlm.nih.gov/21568691/
319.Geavlete, B., et al. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology, 2011. 78: 930.
https://pubmed.ncbi.nlm.nih.gov/21802121/
320.Giulianelli, R., et al. Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up. Arch Ital Urol Androl, 2013. 85: 86.
https://pubmed.ncbi.nlm.nih.gov/23820656/
321.Mamoulakis, C., et al. Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate. Eur Urol, 2013. 63: 667.
https://pubmed.ncbi.nlm.nih.gov/23102675/
322.Xie, C.Y., et al. Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Yonsei Med J, 2012. 53: 734.
https://pubmed.ncbi.nlm.nih.gov/22665339/
323.Komura, K., et al. Incidence of urethral stricture after bipolar transurethral resection of the prostate using TURis: results from a randomised trial. BJU Int, 2015. 115: 644.
https://pubmed.ncbi.nlm.nih.gov/24909399/
324.Kumar, N., et al. Prospective Randomized Comparison of Monopolar TURP, Bipolar TURP and Photoselective Vaporization of the Prostate in Patients with Benign Prostatic Obstruction: 36 Months Outcome. LUTS: Low Urin Tract Symptoms, 2018. 10: 17.
https://pubmed.ncbi.nlm.nih.gov/27168018/
325.Huang, S.-W., et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ (Clin Res ed.), 2019. 367: l5919.
https://pubmed.ncbi.nlm.nih.gov/27168018/
326.National Institute for Health and Care Excellence. The TURis system for transurethral resection of the prostate. NICE GUidelines, 2015.
https://www.nice.org.uk/guidance/mtg53
327.Reich, O., et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol, 2008. 180: 246.
https://pubmed.ncbi.nlm.nih.gov/18499179/
328.Rassweiler, J., et al. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol, 2006. 50: 969.
https://pubmed.ncbi.nlm.nih.gov/16469429/
329.Stucki, P., et al. Bipolar versus monopolar transurethral resection of the prostate: a prospective randomized trial focusing on bleeding complications. J Urol, 2015. 193: 1371.
https://pubmed.ncbi.nlm.nih.gov/25464004/
330.Akman, T., et al. Effects of bipolar and monopolar transurethral resection of the prostate on urinary and erectile function: a prospective randomized comparative study. BJU Int, 2013. 111: 129.
https://pubmed.ncbi.nlm.nih.gov/22672229/
331.El-Assmy, A., et al. Erectile and ejaculatory functions changes following bipolar versus monopolar transurethral resection of the prostate: a prospective randomized study. Int Urol Nephrol, 2018.
50: 1569.
https://pubmed.ncbi.nlm.nih.gov/30083842/
332.Mamoulakis, C., et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int, 2013. 112: 109.
https://pubmed.ncbi.nlm.nih.gov/23490008/
333.Ruhle, A., et al. Safety and Effectiveness of Bipolar Transurethral Resection of the Prostate in Patients under Ongoing Oral Anticoagulation with Coumarins or Antiplatelet Drug Therapy Compared to Patients Without Anticoagulation/Antiplatelet Therapy. J Endourol, 2019. 33: 455.
https://pubmed.ncbi.nlm.nih.gov/30834782/
334.Riedinger, C.B., et al. The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. Prostate Cancer Prostatic Dis, 2019. 22: 303.
https://pubmed.ncbi.nlm.nih.gov/30385836/
335.Bach, T., et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol, 2012. 61: 317.
https://pubmed.ncbi.nlm.nih.gov/22033173/
336.Xia, S.J., et al. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol, 2008. 53: 382.
https://pubmed.ncbi.nlm.nih.gov/17566639/
337.Jiang, H., et al. Safety and Efficacy of Thulium Laser Prostatectomy Versus Transurethral Resection of Prostate for Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. Lower urinary tract symptoms, 2016. 8: 165.
https://pubmed.ncbi.nlm.nih.gov/27619781/
338.Zhang, X., et al. Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. Sci Rep, 2016. 6: 23503.
https://pubmed.ncbi.nlm.nih.gov/27009501/
339.Zhu, Y., et al. Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol, 2015. 33: 509.
https://pubmed.ncbi.nlm.nih.gov/25298242/
340.Zhao, C., et al. Thulium Laser Resection Versus Plasmakinetic Resection of Prostates in the Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. J Laparoendos Adv Surg Tech. Part A, 2016. 26: 789.
https://pubmed.ncbi.nlm.nih.gov/27500451/
341.Deng, Z., et al. Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol, 2018. 36: 1355.
https://pubmed.ncbi.nlm.nih.gov/29651642/
342.Lan, Y., et al. Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis. Lasers Med Sci, 2018. 33: 1411.
https://pubmed.ncbi.nlm.nih.gov/29947009/
343.Hashim, H., et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. The Lancet, 2020. 396: 50.
https://pubmed.ncbi.nlm.nih.gov/32622397/
344.Cui, D., et al. A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. World J Urol, 2014. 32: 683.
https://pubmed.ncbi.nlm.nih.gov/23913094/
345.Sun, F., et al. Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers. World J Urol, 2015. 33: 503.
https://pubmed.ncbi.nlm.nih.gov/25487702/
346.Worthington, J., et al. Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: The UNBLOCS RCT. Health Tech Assess, 2020. 24: 1.
https://pubmed.ncbi.nlm.nih.gov/32901611/
347.Yang, Z., et al. Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. Urology, 2013. 81: 396.
https://pubmed.ncbi.nlm.nih.gov/23374815/
348.Wei, H., et al. Thulium laser resection versus plasmakinetic resection of prostates larger than 80 ml. World J Urol, 2014. 32: 1077.
https://pubmed.ncbi.nlm.nih.gov/24264126/
349.Sener, T.E., et al. Thulium laser vaporesection of the prostate: Can we operate without interrupting oral antiplatelet/ anticoagulant therapy? Invest Clin Urol, 2017. 58: 192.
https://pubmed.ncbi.nlm.nih.gov/28480345/
350.Bansal, A., et al. Holmium Laser vs Monopolar Electrocautery Bladder Neck Incision for Prostates Less Than 30 Grams: A Prospective Randomized Trial. Urology, 2016. 93: 158.
https://pubmed.ncbi.nlm.nih.gov/27058689/
351.Lourenco, T., et al. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol, 2010. 28: 23.
https://pubmed.ncbi.nlm.nih.gov/20033744/
352.Kuntz, R.M., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol, 2008. 53: 160.
https://pubmed.ncbi.nlm.nih.gov/17869409/
353.Naspro, R., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol, 2006. 50: 563.
https://pubmed.ncbi.nlm.nih.gov/16713070/
354.Skolarikos, A., et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol, 2008. 22: 2333.
https://pubmed.ncbi.nlm.nih.gov/18837655/
355.Varkarakis, I., et al. Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology, 2004. 64: 306.
https://pubmed.ncbi.nlm.nih.gov/15302484/
356.Gratzke, C., et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol, 2007. 177: 1419.
https://pubmed.ncbi.nlm.nih.gov/17382744/
357.Chen, S., et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol, 2014. 66: 284.
https://pubmed.ncbi.nlm.nih.gov/24502959/
358.Li, M., et al. Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. PLoS One, 2015. 10: e0121265.
https://pubmed.ncbi.nlm.nih.gov/25826453/
359.Lin, Y., et al. Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol, 2016. 34: 1207.
https://pubmed.ncbi.nlm.nih.gov/26699627/
360.Ou, R., et al. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study. BJU Int, 2013. 112: 239.
https://pubmed.ncbi.nlm.nih.gov/23795788/
361.Rao, J.M., et al. Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia >80 mL: 12-month follow-up results of a randomized clinical trial. Urology, 2013. 82: 176.
https://pubmed.ncbi.nlm.nih.gov/23601443/
362.Geavlete, B., et al. Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases? J Endourol, 2015. 29: 323.
https://pubmed.ncbi.nlm.nih.gov/25111385/
363.Geavlete, B., et al. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison. BJU Int, 2013. 111: 793.
https://pubmed.ncbi.nlm.nih.gov/23469933/
364.Salonia, A., et al. Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. Urology, 2006. 68: 302.
https://pubmed.ncbi.nlm.nih.gov/16904441/
365.Zhang, Y., et al. Transurethral holmium laser enucleation for prostate adenoma greater than 100 g. Zhonghua Nan Ke Xue, 2007. 13: 1091.
https://pubmed.ncbi.nlm.nih.gov/18284057/
366.Tubaro, A., et al. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol, 2001. 166: 172.
https://pubmed.ncbi.nlm.nih.gov/11435849/
367.Zhang, K., et al. Plasmakinetic Vapor Enucleation of the Prostate with Button Electrode versus Plasmakinetic Resection of the Prostate for Benign Prostatic Enlargement >90 ml: Perioperative and 3-Month Follow-Up Results of a Prospective, Randomized Clinical Trial. Urol Int, 2015. 95: 260.
https://pubmed.ncbi.nlm.nih.gov/26044933/
368.Wang, Z., et al. A prospective, randomised trial comparing transurethral enucleation with bipolar system (TUEB) to monopolar resectoscope enucleation of the prostate for symptomatic benign prostatic hyperplasia. Biomed Res, 2017. 28.
369.Neill, M.G., et al. Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. Urology, 2006. 68: 1020.
https://pubmed.ncbi.nlm.nih.gov/17095078/
370.Ran, L., et al. Comparison of fluid absorption between transurethral enucleation and transurethral resection for benign prostate hyperplasia. Urol Int, 2013. 91: 26.
https://pubmed.ncbi.nlm.nih.gov/23571450/
371.Zhao, Z., et al. A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. Eur Urol, 2010. 58: 752.
https://pubmed.ncbi.nlm.nih.gov/20800340/
372.Li, K., et al. A Novel Modification of Transurethral Enucleation and Resection of the Prostate in Patients With Prostate Glands Larger than 80 mL: Surgical Procedures and Clinical Outcomes. Urology, 2018. 113: 153.
https://pubmed.ncbi.nlm.nih.gov/29203184/
373.Luo, Y.H., et al. Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients. Urology, 2014. 84: 904.
https://pubmed.ncbi.nlm.nih.gov/25150180/
374.Zhu, L., et al. Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. J Urol, 2013. 189: 1427.
https://pubmed.ncbi.nlm.nih.gov/23123549/
375.Zhang, Y., et al. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis, 2019. 22: 493.
https://pubmed.ncbi.nlm.nih.gov/30816336/
376.Arcaniolo, D., et al. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol, 2020. 38: 1177.
https://pubmed.ncbi.nlm.nih.gov/31346761/
377.Tian, J., et al. Comparative study of the effectiveness and safety of transurethral bipolar plasmakinetic enucleation of the prostate and transurethral bipolar plasmakinetic resection of the prostate for massive benign prostate hyperplasia (>80 ml). Med Sci Monitor, 2020. 26: e921272.
https://pubmed.ncbi.nlm.nih.gov/32339160/
378.Samir, M., et al. Two-year Follow-up in Bipolar Transurethral Enucleation and Resection of the Prostate in Comparison with Bipolar Transurethral Resection of the Prostate in Treatment of Large Prostates. Randomized Controlled Trial. Urology, 2019. 133: 192.
https://pubmed.ncbi.nlm.nih.gov/31404581/
379.Liu, Q.-L., et al. Comparison of the Transurethral Resection of the Prostate by Traditional Versus Preserved Urethral Mucosa of the Prostatic Apex. J Endourol, 2020. 34: 482.
https://pubmed.ncbi.nlm.nih.gov/31964193/
380.Gilling, P.J., et al. Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. J Endourol, 1995. 9: 151.
https://pubmed.ncbi.nlm.nih.gov/7633476/
381.Tan, A., et al. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg, 2007. 94: 1201.
https://pubmed.ncbi.nlm.nih.gov/17729384/
382.Yin, L., et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol, 2013. 27: 604.
https://pubmed.ncbi.nlm.nih.gov/23167266/
383.Qian, X., et al. Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis. Aging Male, 2017. 20: 184.
https://pubmed.ncbi.nlm.nih.gov/28368238/
384.Chen, Y.B., et al. A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol, 2013. 189: 217.
https://pubmed.ncbi.nlm.nih.gov/23174256/
385.Gilling, P.J., et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int, 2012. 109: 408.
https://pubmed.ncbi.nlm.nih.gov/21883820/
386.Elshal, A.M., et al. Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. BJU Int, 2020. 126: 731.
https://pubmed.ncbi.nlm.nih.gov/32633020/
387.Higazy, A., et al. Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial. Int
J Urol, 2021. 28: 333.
https://pubmed.ncbi.nlm.nih.gov/33327043/
388.Lourenco, T., et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ, 2008. 337: a449.
https://pubmed.ncbi.nlm.nih.gov/18595932/
389.Huang, K.C., et al. Combination of Thulium Laser Incision and Bipolar Resection Offers Higher Resection Velocity than Bipolar Resection Alone in Large Prostates. Urol J, 2019. 16: 397.
https://pubmed.ncbi.nlm.nih.gov/30318570/
390.Heidar, N.A., et al. Laser enucleation of the prostate versus transurethral resection of the prostate: perioperative outcomes from the ACS NSQIP database. World J Urol, 2020. 38: 2891.
https://pubmed.ncbi.nlm.nih.gov/32036397/
391.Bozzini, G., et al. A prospective multicenter randomized comparison between Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP). World J Urol, 2020.
https://pubmed.ncbi.nlm.nih.gov/32997262/
392.El Tayeb, M.M., et al. Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation. J Endourol, 2016. 30: 805.
https://pubmed.ncbi.nlm.nih.gov/27065437/
393.Sun, J., et al. Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT). World J Urol, 2018. 36: 271.
https://pubmed.ncbi.nlm.nih.gov/29138929/
394.Liu, Y., et al. Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and meta-analysis. J Endourol, 2020. 34: 1064.
https://pubmed.ncbi.nlm.nih.gov/32242462/
395.Cacciamani, G.E., et al. Anterograde ejaculation preservation after endoscopic treatments in patients with bladder outlet obstruction: systematic review and pooled-analysis of randomized clinical trials. Minerva Urol Nefrol, 2019. 71: 427.
https://pubmed.ncbi.nlm.nih.gov/31487977/
396.Briganti, A., et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. J Urol, 2006. 175: 1817.
https://pubmed.ncbi.nlm.nih.gov/16600770/
397.Li, Z., et al. The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis. Medicine (Baltimore), 2016. 95: e3862.
https://pubmed.ncbi.nlm.nih.gov/27310968/
398.Elshal, A.M., et al. Prospective controlled assessment of men’s sexual function changes following Holmium laser enucleation of the prostate for treatment of benign prostate hyperplasia. Int Urol Nephrol, 2017. 49: 1741.
https://pubmed.ncbi.nlm.nih.gov/28780626/
399.Kim, M., et al. Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. Int J Impot Res, 2015. 27: 20.
https://pubmed.ncbi.nlm.nih.gov/25007827/
400.Elzayat, E.A., et al. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol, 2007. 52: 1465.
https://pubmed.ncbi.nlm.nih.gov/17498867/
401.Du, C., et al. Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China. J Endourol, 2008. 22: 1031.
https://pubmed.ncbi.nlm.nih.gov/18377236/
402.Robert, G., et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int, 2016. 117: 495.
https://pubmed.ncbi.nlm.nih.gov/25781490/
403.Aho, T., et al. Description of a modular mentorship programme for holmium laser enucleation of the prostate. World J Urol, 2015. 33: 497.
https://pubmed.ncbi.nlm.nih.gov/25271105/
404.Enikeev, D., et al. A Randomized Trial Comparing The Learning Curve of 3 Endoscopic Enucleation Techniques (HoLEP, ThuFLEP, and MEP) for BPH Using Mentoring Approach-Initial Results. Urology, 2018. 121: 51.
https://pubmed.ncbi.nlm.nih.gov/30053397/
405.Yang, Z., et al. Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. Lasers Med Sci, 2016. 31: 1797.
https://pubmed.ncbi.nlm.nih.gov/27677474/
406.Hartung, F.O., et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2021.
https://pubmed.ncbi.nlm.nih.gov/33840611/
407.Zhang, F., et al. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology, 2012. 79: 869.
https://pubmed.ncbi.nlm.nih.gov/22342411/
408.Feng, L., et al. Thulium Laser Enucleation Versus Plasmakinetic Enucleation of the Prostate: A Randomized Trial of a Single Center. J Endourol, 2016. 30: 665.
https://pubmed.ncbi.nlm.nih.gov/26886719/
409.Bach, T., et al. Thulium:YAG vapoenucleation in large volume prostates. J Urol, 2011. 186: 2323.
https://pubmed.ncbi.nlm.nih.gov/22014812/
410.Hauser, S., et al. Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. Urol Int, 2012. 88: 390.
https://pubmed.ncbi.nlm.nih.gov/22627127/
411.Netsch, C., et al. Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol, 2014. 32: 165.
https://pubmed.ncbi.nlm.nih.gov/23657354/
412.Netsch, C., et al. Comparison of 120-200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate. J Endourol, 2012. 26: 224.
https://pubmed.ncbi.nlm.nih.gov/22191688/
413.Xiao, K.W., et al. Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis. Lasers Med Sci, 2019.
https://pubmed.ncbi.nlm.nih.gov/30604345/
414.Hanada, I., et al. Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study. Int J Urol, 2020. 27: 974.
https://pubmed.ncbi.nlm.nih.gov/33241599/
415.Chang, C.H., et al. Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study. BMC Urol, 2015. 15: 40.
https://pubmed.ncbi.nlm.nih.gov/25956819/
416.Gross, A.J., et al. Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol, 2013. 63: 859.
https://pubmed.ncbi.nlm.nih.gov/23245687/
417.Lusuardi, L., et al. Safety and efficacy of Eraser laser enucleation of the prostate: preliminary report. J Urol, 2011. 186: 1967.
https://pubmed.ncbi.nlm.nih.gov/21944122/
418.Zhang, J., et al. 1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. J Endourol, 2019. 33: 211.
https://pubmed.ncbi.nlm.nih.gov/30489151/
419.Zou, Z., et al. Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results. World J Urol, 2018.
https://pubmed.ncbi.nlm.nih.gov/29459994/
420.Xu, A., et al. A randomized trial comparing diode laser enucleation of the prostate with plasmakinetic enucleation and resection of the prostate for the treatment of benign prostatic hyperplasia. J Endourol, 2013. 27: 1254.
https://pubmed.ncbi.nlm.nih.gov/23879477/
421.Wu, G., et al. A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up. Lasers Med Sci, 2016. 31: 599.
https://pubmed.ncbi.nlm.nih.gov/26822403/
422.He, G., et al. Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up. J Endourol, 2019. 33: 843.
https://pubmed.ncbi.nlm.nih.gov/31298571/
423.Mariano, M.B., et al. Laparoscopic prostatectomy with vascular control for benign prostatic hyperplasia. J Urol, 2002. 167: 2528.
https://pubmed.ncbi.nlm.nih.gov/11992078/
424.Sotelo, R., et al. Robotic simple prostatectomy. J Urol, 2008. 179: 513.
https://pubmed.ncbi.nlm.nih.gov/18076926/
425.Lucca, I., et al. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol, 2015. 33: 563.
https://pubmed.ncbi.nlm.nih.gov/24879405/
426.Li, J., et al. Comparison Between Minimally Invasive Simple Prostatectomy and Open Simple Prostatectomy for Large Prostates: A Systematic Review and Meta-Analysis of Comparative Trials.
J Endourol, 2019. 33: 767.
https://pubmed.ncbi.nlm.nih.gov/31244334/
427.Velotti, G., et al. Holmium laser enucleation of prostate versus minimally invasive simple prostatectomy for large volume (>= 120 ml) prostate glands: a prospective multicenter randomized study. Miner Minerva Urol Nefrol, 2020. 73: 638.
https://pubmed.ncbi.nlm.nih.gov/33200899/
428.Sorokin, I., et al. Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. J Endourol, 2017. 31: 1164.
https://pubmed.ncbi.nlm.nih.gov/28854815/
429.Stoddard, M.D., et al. Standardization of 532 nm Laser Terminology for Surgery in Benign Prostatic Hyperplasia: A Systematic Review. J Endourol, 2020. 34: 121.
https://pubmed.ncbi.nlm.nih.gov/31880953/
430.Gomez Sancha, F., et al. Common trend: move to enucleation-Is there a case for GreenLight enucleation? Development and description of the technique. World J Urol, 2015. 33: 539.
https://pubmed.ncbi.nlm.nih.gov/24929643/
431.Law, K.W., et al. Anatomic GreenLight laser vaporization-incision technique for benign prostatic hyperplasia using the XPS LBO-180W system: How I do it. Can J Urol, 2019. 26: 9963.
https://pubmed.ncbi.nlm.nih.gov/31629449/
432.Elshal, A.M., et al. Prospective Assessment of Learning Curve of Holmium Laser Enucleation of the Prostate for Treatment of Benign Prostatic Hyperplasia Using a Multidimensional Approach. J Urol, 2017. 197: 1099.
https://pubmed.ncbi.nlm.nih.gov/27825972/
433.Botto, H., et al. Electrovaporization of the prostate with the Gyrus device. J Endourol, 2001. 15: 313.
https://pubmed.ncbi.nlm.nih.gov/11339400/
434.Reich, O., et al. Plasma Vaporisation of the Prostate: Initial Clinical Results. Eur Urol, 2010. 57: 693.
https://pubmed.ncbi.nlm.nih.gov/50533904/
435.Reich, O., et al. In vitro comparison of transurethral vaporization of the prostate (TUVP), resection of the prostate (TURP), and vaporization-resection of the prostate (TUVRP). Urol Res, 2002. 30: 15.
https://pubmed.ncbi.nlm.nih.gov/11942320/
436.Gallucci, M., et al. Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. Eur Urol, 1998. 33: 359.
https://pubmed.ncbi.nlm.nih.gov/9612677/
437.Poulakis, V., et al. Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. BJU Int, 2004. 94: 89.
https://pubmed.ncbi.nlm.nih.gov/15217438/
438.Dunsmuir, W.D., et al. Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. Prostate Cancer Prostatic Dis, 2003. 6: 182.
https://pubmed.ncbi.nlm.nih.gov/12806380/
439.Fung, B.T., et al. Prospective randomized controlled trial comparing plasmakinetic vaporesection and conventional transurethral resection of the prostate. Asian J Surg, 2005. 28: 24.
https://pubmed.ncbi.nlm.nih.gov/15691793/
440.Karaman, M.I., et al. Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. J Endourol, 2005. 19: 734.
https://pubmed.ncbi.nlm.nih.gov/16053367/
441.Hon, N.H., et al. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. J Urol, 2006. 176: 205.
https://pubmed.ncbi.nlm.nih.gov/16753403/
442.Kaya, C., et al. The long-term results of transurethral vaporization of the prostate using plasmakinetic energy. BJU Int, 2007. 99: 845.
https://pubmed.ncbi.nlm.nih.gov/46439565/
443.Geavlete, B., et al. Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: ‘the better choice’ in benign prostatic hyperplasia? BJU Int, 2010. 106: 1695.
https://pubmed.ncbi.nlm.nih.gov/20518763/
444.Nuhoglu, B., et al. The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. Urol Int, 2011. 87: 400.
https://pubmed.ncbi.nlm.nih.gov/51717888/
445.Zhang, S.Y., et al. Efficacy and safety of bipolar plasma vaporization of the prostate with “button-type” electrode compared with transurethral resection of prostate for benign prostatic hyperplasia. Chin Med J (Engl), 2012. 125: 3811.
https://pubmed.ncbi.nlm.nih.gov/23106879/
446.Falahatkar, S., et al. Bipolar transurethral vaporization: a superior procedure in benign prostatic hyperplasia: a prospective randomized comparison with bipolar TURP. Int Braz J Urol, 2014. 40: 346.
https://pubmed.ncbi.nlm.nih.gov/25010300/
447.Geavlete, B., et al. Continuous vs conventional bipolar plasma vaporisation of the prostate and standard monopolar resection: A prospective, randomised comparison of a new technological advance. BJU Int, 2014. 113: 288.
https://pubmed.ncbi.nlm.nih.gov/52898764/
448.Yip, S.K., et al. A randomized controlled trial comparing the efficacy of hybrid bipolar transurethral vaporization and resection of the prostate with bipolar transurethral resection of the prostate.
J Endourol, 2011. 25: 1889.
https://pubmed.ncbi.nlm.nih.gov/21923418/
449.Elsakka, A.M., et al. A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate. Arab J Urol, 2016. 14: 280.
https://pubmed.ncbi.nlm.nih.gov/27900218/
450.Lee, S.W., et al. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: A quality and meta-analysis. Int Neurourol J, 2013. 17: 59.
https://pubmed.ncbi.nlm.nih.gov/23869269/
451.Wroclawski, M.L., et al. ‘Button type’ bipolar plasma vaporisation of the prostate compared with standard transurethral resection: A systematic review and meta-analysis of short-term outcome studies. BJU Int, 2016. 117: 662.
https://pubmed.ncbi.nlm.nih.gov/26299915/
452.Robert, G., et al. Bipolar plasma vaporization of the prostate: ready to replace GreenLight? A systematic review of randomized control trials. World J Urol, 2015. 33: 549.
https://pubmed.ncbi.nlm.nih.gov/25159871/
453.Thangasamy, I.A., et al. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol, 2012. 62: 315.
https://pubmed.ncbi.nlm.nih.gov/22575913/
454.Kang, D.H., et al. A Systematic Review and Meta-Analysis of Functional Outcomes and Complications Following the Photoselective Vaporization of the Prostate and Monopolar Transurethral Resection of the Prostate. World J Mens Health, 2016. 34: 110.
https://pubmed.ncbi.nlm.nih.gov/27574594/
455.Zhou, Y., et al. Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci, 2016. 31: 485.
https://pubmed.ncbi.nlm.nih.gov/26868032/
456.Thomas, J.A., et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol, 2016. 69: 94.
https://pubmed.ncbi.nlm.nih.gov/26283011/
457.Elmansy, H., et al. Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol, 2012. 188: 216.
https://pubmed.ncbi.nlm.nih.gov/22591968/
458.Ghobrial, F.K., et al. A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years. BJU Int, 2020. 125: 144.
https://pubmed.ncbi.nlm.nih.gov/31621175/
459.Al-Ansari, A., et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol, 2010. 58: 349.
https://pubmed.ncbi.nlm.nih.gov/20605316/
460.Chung, D.E., et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol, 2011. 186: 977.
https://pubmed.ncbi.nlm.nih.gov/21791350/
461.Reich, O., et al. High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol, 2005. 173: 158.
https://pubmed.ncbi.nlm.nih.gov/15592063/
462.Ruszat, R., et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol, 2007. 51: 1031.
https://pubmed.ncbi.nlm.nih.gov/16945475/
463.Sandhu, J.S., et al. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol, 2005. 19: 1196.
https://pubmed.ncbi.nlm.nih.gov/16359214/
464.Lee, D.J., et al. Laser Vaporization of the Prostate With the 180-W XPS-Greenlight Laser in Patients With Ongoing Platelet Aggregation Inhibition and Oral Anticoagulation. Urology, 2016. 91: 167.
https://pubmed.ncbi.nlm.nih.gov/26829717/
465.Jackson, R.E., et al. Risk factors for delayed hematuria following photoselective vaporization of the prostate. J Urol, 2013. 190: 903.
https://pubmed.ncbi.nlm.nih.gov/23538242/
466.Knapp, G.L., et al. Perioperative adverse events in patients on continued anticoagulation undergoing photoselective vaporisation of the prostate with the 180-W Greenlight lithium triborate laser. BJU Int, 2017. 119: 33.
https://pubmed.ncbi.nlm.nih.gov/28544292/
467.Woo, H., et al. Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (>80 ml). Eur Urol Suppl, 2008. 7: 378.
https://www.eu-openscience.europeanurology.com/article/S1569-9056(08)00027-4/pdf
468.Rajbabu, K., et al. Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100 mL. BJU Int, 2007. 100: 593.
https://pubmed.ncbi.nlm.nih.gov/17511771/
469.Ruszat, R., et al. Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol, 2006. 50: 1040.
https://pubmed.ncbi.nlm.nih.gov/16481099/
470.Alivizatos, G., et al. Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. Eur Urol, 2008. 54: 427.
https://pubmed.ncbi.nlm.nih.gov/18069117/
471.Bouchier-Hayes, D.M., et al. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol, 2006. 20: 580.
https://pubmed.ncbi.nlm.nih.gov/16903819/
472.Bruyere, F., et al. Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. Eur Urol, 2010. 58: 207.
https://pubmed.ncbi.nlm.nih.gov/20466480/
473.Razzaghi, M.R., et al. Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: randomized clinical trial with 2-year follow-up. Urology, 2014. 84: 526.
https://pubmed.ncbi.nlm.nih.gov/25168526/
474.Cetinkaya, M., et al. 980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study. Urol J, 2015. 12: 2355.
https://pubmed.ncbi.nlm.nih.gov/26571321/
475.Chiang, P.H., et al. GreenLight HPS laser 120-W versus diode laser 200-W vaporization of the prostate: comparative clinical experience. Lasers Surg Med, 2010. 42: 624.
https://pubmed.ncbi.nlm.nih.gov/20806388/
476.Ruszat, R., et al. Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia. BJU Int, 2009. 104: 820.
https://pubmed.ncbi.nlm.nih.gov/19239441/
477.Seitz, M., et al. The diode laser: a novel side-firing approach for laser vaporisation of the human prostate--immediate efficacy and 1-year follow-up. Eur Urol, 2007. 52: 1717.
https://pubmed.ncbi.nlm.nih.gov/17628326/
478.MacRae, C., et al. How I do it: Aquablation of the prostate using the AQUABEAM system. Can
J Urol, 2016. 23: 8590.
https://pubmed.ncbi.nlm.nih.gov/27995858/
479.Gilling, P., et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J Urol, 2018. 199: 1252.
https://pubmed.ncbi.nlm.nih.gov/29360529/
480.Kasivisvanathan, V., et al. Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. Can J Urol, 2018. 25: 9317.
https://pubmed.ncbi.nlm.nih.gov/29900819/
481.Gilling, P.J., et al. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. Urology, 2019. 125: 169.
https://pubmed.ncbi.nlm.nih.gov/30552937/
482.Gilling, P., et al. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Adv Ther, 2019. 36: 1326.
https://pubmed.ncbi.nlm.nih.gov/31028614/
483.Gilling, P., et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol, 2020. 27: 10072.
https://pubmed.ncbi.nlm.nih.gov/32065861/
484.Bach, T., et al. Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol, 2019. 37: 1369.
https://pubmed.ncbi.nlm.nih.gov/30288598/
485.Plante, M., et al. Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU Int, 2019. 123: 651.
https://pubmed.ncbi.nlm.nih.gov/29862630/
486.Nguyen, D.-D., et al. WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cm3 and 80-150-cm3 Prostates. Eur Urol Open Sci, 2021. 25: 21.
https://pubmed.ncbi.nlm.nih.gov/34337500/
487.Pimentel, M.A., et al. Urodynamic Outcomes After Aquablation. Urology, 2019. 126: 165.
https://pubmed.ncbi.nlm.nih.gov/30721737/
488.Desai, M., et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int, 2019. 124: 321.
https://pubmed.ncbi.nlm.nih.gov/30734990/
489.Nguyen, D.-D., et al. Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates. BJU Int, 2020. 125: 112.
https://pubmed.ncbi.nlm.nih.gov/31599044/
490.Bhojani, N., et al. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology, 2019. 129: 1.
https://pubmed.ncbi.nlm.nih.gov/31059728/
491.Abt, D., et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ, 2018. 361: k2338.
https://pubmed.ncbi.nlm.nih.gov/29921613/
492.Zhang, J.L., et al. Effectiveness of Contrast-enhanced MR Angiography for Visualization of the Prostatic Artery prior to Prostatic Arterial Embolization. Radiology, 2019: 181524.
https://pubmed.ncbi.nlm.nih.gov/30806596/
493.Pisco, J.M., et al. Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia. Eur Urol, 2020. 77: 354.
https://pubmed.ncbi.nlm.nih.gov/31831295/
494.Zumstein, V., et al. Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus, 2018. 5: 1091.
https://pubmed.ncbi.nlm.nih.gov/30292422/
495.Knight, G.M., et al. Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. CardioVasc Int Radiol, 2021. 44: 183.
https://pubmed.ncbi.nlm.nih.gov/33078236/
496.Xiang, P., et al. A Systematic Review and Meta-analysis of Prostatic Urethral Lift for Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol Open Sci, 2020. 19: 3.
https://pubmed.ncbi.nlm.nih.gov/34337448/
497.Abt, D., et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol, 2021. 80: 34.
https://pubmed.ncbi.nlm.nih.gov/33612376/
498.Ayyagari, R., et al. Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. Urology, 2020. 136: 212.
https://pubmed.ncbi.nlm.nih.gov/31734349/
499.Shim, S.R., et al. Efficacy and Safety of Prostatic Arterial Embolization: Systematic Review with Meta-Analysis and Meta-Regression. J Urol, 2017. 197: 465.
https://pubmed.ncbi.nlm.nih.gov/27592008/
500.Jiang, Y.L., et al. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: A meta-analysis. BMC Urol, 2019. 19: 11.
https://pubmed.ncbi.nlm.nih.gov/31522236/
501.Xu, X.J., et al. An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol, 2020.
38: 2455.
https://pubmed.ncbi.nlm.nih.gov/31813027/
502.Moreira, A.M., et al. A Review of Adverse Events Related to Prostatic Artery Embolization for Treatment of Bladder Outlet Obstruction Due to BPH. Cardiovasc Intervent Radiol, 2017. 40: 1490.
https://pubmed.ncbi.nlm.nih.gov/28795212/
503.Ray, A.F., et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int, 2018. 122: 270.
https://pubmed.ncbi.nlm.nih.gov/29645352/
504.Zumstein, V., et al. Radiation Exposure During Prostatic Artery Embolisation: A Systematic Review and Calculation of Associated Risks. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/32418877/
505.National Institute for Health and Care Excellence. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE Guidance, 2018.
https://www.nice.org.uk/guidance/ipg611
506.Abt, D., et al. Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial. BJU Int, 2019. 124: 134.
https://pubmed.ncbi.nlm.nih.gov/30499637/
507.McVary, K.T., et al. Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study. J Sex Med, 2016. 13: 924.
https://pubmed.ncbi.nlm.nih.gov/27129767/
508.Roehrborn, C.G., et al. Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol, 2017. 197: 1507.
https://pubmed.ncbi.nlm.nih.gov/27993667/
509.McVary, K.T., et al. Rezum Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology, 2019. 126: 171.
https://pubmed.ncbi.nlm.nih.gov/30677455/
510.Kang, T.W., et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev, 2020.
3: CD013251.
https://pubmed.ncbi.nlm.nih.gov/32212174/
511.Miller, L.E., et al. Water vapor thermal therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: Systematic review and meta-analysis. Medicine, 2020. 99: e21365.
https://pubmed.ncbi.nlm.nih.gov/32791742/
512.Chin, P.T., et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology, 2012. 79: 5.
https://pubmed.ncbi.nlm.nih.gov/22202539/
513.McNicholas, T.A., et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol, 2013. 64: 292.
https://pubmed.ncbi.nlm.nih.gov/23357348/
514.Roehrborn, C.G., et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol, 2013. 190: 2161.
https://pubmed.ncbi.nlm.nih.gov/23764081/
515.Woo, H.H., et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int, 2011. 108: 82.
https://pubmed.ncbi.nlm.nih.gov/21554526/
516.Woo, H.H., et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med, 2012. 9: 568.
https://pubmed.ncbi.nlm.nih.gov/22172161/
517.Perera, M., et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol, 2015. 67: 704.
https://pubmed.ncbi.nlm.nih.gov/25466940/
518.Jung, J.H., et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev, 2019. 5: CD012832.
https://pubmed.ncbi.nlm.nih.gov/31128077/
519.Roehrborn, C.G., et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol, 2015.
22: 7772.
https://pubmed.ncbi.nlm.nih.gov/26068624/
520.Roehrborn, C.G., et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol, 2017. 24: 8802.
https://pubmed.ncbi.nlm.nih.gov/28646935/
521.Eure, G., et al. Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. J Endourol, 2019. 33: 576.
https://pubmed.ncbi.nlm.nih.gov/31115257/
522.Sonksen, J., et al. Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study. Eur Urol, 2015.
68: 643.
https://pubmed.ncbi.nlm.nih.gov/25937539/
523.Miller, L.E., et al. Surgical Reintervention Rate after Prostatic Urethral Lift: Systematic Review and Meta-Analysis Involving over 2,000 Patients. J Urol, 2020. 204: 1019.
https://pubmed.ncbi.nlm.nih.gov/32396049/
524.Rukstalis, D., et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis, 2019. 22: 411.
https://pubmed.ncbi.nlm.nih.gov/30542055/
525.Magistro, G., et al. New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol, 2015. 12: 461.
https://pubmed.ncbi.nlm.nih.gov/26195444/
526.Shim, S.R., et al. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol, 2016. 48: 19.
https://pubmed.ncbi.nlm.nih.gov/26560471/
527.Elhilali, M.M., et al. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol, 2013. 189: 1421.
https://pubmed.ncbi.nlm.nih.gov/23142202/
528.Denmeade, S.R., et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol, 2011. 59: 747.
https://pubmed.ncbi.nlm.nih.gov/21129846/
529.Shore, N., et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol, 2018. 36: 801.
https://pubmed.ncbi.nlm.nih.gov/29380128/
530.El-Dakhakhny, A.S., et al. Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study. Arab J Urol, 2019. 17: 270.
https://pubmed.ncbi.nlm.nih.gov/31723444/
531.Porpiglia, F., et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int, 2015. 116: 278.
https://pubmed.ncbi.nlm.nih.gov/25382816/
532.Porpiglia, F., et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int, 2018. 122: 106.
https://pubmed.ncbi.nlm.nih.gov/29359881/
533.Chughtai, B., et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology, 2021. 153: 270.
https://pubmed.ncbi.nlm.nih.gov/33373708/
534.Porpiglia, F., et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int, 2019. 123: 1061.
https://pubmed.ncbi.nlm.nih.gov/30382600/
535.Sakalis, V.I., et al. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol, 2017. 72: 757.
https://pubmed.ncbi.nlm.nih.gov/28666669/
536.Hashim, H., et al. International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn, 2019. 38: 499.
https://pubmed.ncbi.nlm.nih.gov/30644584/
537.Marshall, S.D., et al. Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. Urology, 2015. 85: 1291.
https://pubmed.ncbi.nlm.nih.gov/25881866/
538.Cannon, A., et al. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int, 1999. 84: 20.
https://pubmed.ncbi.nlm.nih.gov/10444118/
539.Han, J., et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev, 2017.
10: CD012059.
https://pubmed.ncbi.nlm.nih.gov/29055129/
540.Weiss, J.P., et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol, 2013. 190: 965.
https://pubmed.ncbi.nlm.nih.gov/23454402/
541.Sand, P.K., et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol, 2013. 190: 958.
https://pubmed.ncbi.nlm.nih.gov/23454404/
542.Juul, K.V., et al. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU Int, 2017. 119: 776.
https://pubmed.ncbi.nlm.nih.gov/27862898/
543.Cohn, J.A., et al. Desmopressin acetate nasal spray for adults with nocturia. Expert Rev Clin Pharmacol, 2017. 10: 1281.
https://pubmed.ncbi.nlm.nih.gov/29048257/
544.Djavan, B., et al. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. Eur Urol Suppl, 2005. 4: 1119.
https://www.tqfarma.com/Portals/0/docs/pdf/The%20Impact%20of%20Tam%20(OCAS)%20on%20Nocturia%20and%20the%20QO%20Sleep-%20Preliminary.pdf
545.Yokoyama, O., et al. Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder. Urology, 2014. 83: 750.
https://pubmed.ncbi.nlm.nih.gov/24518285/
546.Yokoyama, O., et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol, 2011. 186: 170.
https://pubmed.ncbi.nlm.nih.gov/21575976/
547.Johnson, T.M., 2nd, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol, 2007. 178: 2045.
https://pubmed.ncbi.nlm.nih.gov/17869295/
548.Oelke, M., et al. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. World J Urol, 2014. 32: 1141.
https://pubmed.ncbi.nlm.nih.gov/24903347/
549.Oelke, M., et al. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World J Urol, 2014. 32: 1127.
https://pubmed.ncbi.nlm.nih.gov/24504761/
550.Drake, M.J., et al. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol, 2004. 171: 1199.
https://pubmed.ncbi.nlm.nih.gov/14767300/
551.Reynard, J.M., et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol, 1998. 81: 215.
https://pubmed.ncbi.nlm.nih.gov/9488061/
552.Falahatkar, S., et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology, 2008. 72: 813.
https://pubmed.ncbi.nlm.nih.gov/18692876/
553.Sigurdsson, S., et al. A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men. Scand J Urol, 2013. 47: 26.
https://pubmed.ncbi.nlm.nih.gov/23323790/
554.D’Ancona, C., et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn, 2019. 38: 433.
https://pubmed.ncbi.nlm.nih.gov/30681183/
555.Helfand, B.T., et al. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study. J Urol, 2018. 200: 397.
https://pubmed.ncbi.nlm.nih.gov/29477718/
556.Shamliyan, T.A., et al. Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol, 2009. 11: 145.
https://pubmed.ncbi.nlm.nih.gov/19918340/
557.Hester, A.G., et al. Male Incontinence: The Etiology or Basis of Treatment. Eur Urol Focus, 2017. 3: 377.
https://pubmed.ncbi.nlm.nih.gov/29249687/
558.Herschorn, S., et al. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int, 2008. 101: 52.
https://pubmed.ncbi.nlm.nih.gov/17908260/
559.Espuna-Pons, M., et al. [Prevalence of urinary incontinence in Catalonia, Spain]. Med Clin (Barc), 2009. 133: 702.
https://pubmed.ncbi.nlm.nih.gov/19656535/
560.Hampel, C., et al. Epidemiology and etiology of male urinary incontinence. Urologe A, 2010. 49: 481.
https://pubmed.ncbi.nlm.nih.gov/20376650/
561.Abrams, P., et al. 5th International Consultation on Incontinence, Paris, February 2012.
562.Sato, Y., et al. Simple and reliable predictor of urinary continence after radical prostatectomy: serial measurement of urine loss ratio after catheter removal. Int J Urol, 2014. 21: 647.
https://pubmed.ncbi.nlm.nih.gov/24612261/
563.Shy, M., et al. Objective Evaluation of Overactive Bladder: Which Surveys Should I Use? Curr Bladder Dysfunct Rep, 2013. 8: 45.
https://pubmed.ncbi.nlm.nih.gov/23439804/
564.Soljanik, I., et al. Imaging for urinary incontinence. Urologe A, 2015. 54: 963.
https://pubmed.ncbi.nlm.nih.gov/26162272/
565.Wyman, J.F., et al. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract, 2009. 63: 1177.
https://pubmed.ncbi.nlm.nih.gov/19575724/
566.Breyer, B.N., et al. Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial. J Urol, 2014. 192: 144.
https://pubmed.ncbi.nlm.nih.gov/24533998/
567.Imamura, M., et al. Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev, 2015. 2015: CD003505.
https://pubmed.ncbi.nlm.nih.gov/26630349/
568.Townsend, M.K., et al. Fluid intake and risk of stress, urgency, and mixed urinary incontinence. Am
J Obstet Gynecol, 2011. 205: 73.e1.
https://pubmed.ncbi.nlm.nih.gov/21481835/
569.Hannestad, Y.S., et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG, 2003. 110: 247.
https://pubmed.ncbi.nlm.nih.gov/12628262/
570.Bryant, C.M., et al. Caffeine reduction education to improve urinary symptoms. Br J Nurs, 2002.
11: 560.
https://pubmed.ncbi.nlm.nih.gov/11979209/
571.Chughtai, B., et al. Prevalence of and Risk Factors for Urinary Incontinence in Home Hospice Patients. Eur Urol, 2019. 75: 268.
https://pubmed.ncbi.nlm.nih.gov/30482670/
572.Held, F., et al. Polypharmacy in older adults: Association Rule and Frequent-Set Analysis to evaluate concomitant medication use. Pharmacol Res, 2017. 116: 39.
https://pubmed.ncbi.nlm.nih.gov/27988385/
573.Schnelle, J.F., et al. A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. J Am Geriatr Soc, 2010. 58: 1504.
https://pubmed.ncbi.nlm.nih.gov/20653804/
574.Brazzelli, M., et al. Absorbent products for containing urinary and/or fecal incontinence in adults.
J Wound Ostomy Continence Nurs, 2002. 29: 45.
https://pubmed.ncbi.nlm.nih.gov/11810074/
575.Fader, M., et al. Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product designs. Health Technol Assess, 2008. 12: iii.
https://pubmed.ncbi.nlm.nih.gov/18547500/
576.Jahn, P., et al. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database Syst Rev, 2012. 10: CD004997.
https://pubmed.ncbi.nlm.nih.gov/23076911/
577.Hunter, K.F., et al. Long-term bladder drainage: Suprapubic catheter versus other methods: a scoping review. Neurourol Urodyn, 2013. 32: 944.
https://pubmed.ncbi.nlm.nih.gov/23192860/
578.Prieto, J., et al. Catheter designs, techniques and strategies for intermittent catheterisation: What is the evidence for preventing symptomatic UTI and other complications? A Cochrane systematic review. Eur Urol Suppl, 2014. 13: e762.
http://lib.ajaums.ac.ir/booklist/1-s2.0-S156990561460751X-main.pdf
579.Macaulay, M., et al. A trial of devices for urinary incontinence after treatment for prostate cancer. BJU Int, 2015. 116: 432.
https://pubmed.ncbi.nlm.nih.gov/25496354/
580.Eustice, S., et al. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev, 2000: CD002113.
https://pubmed.ncbi.nlm.nih.gov/10796861/
581.Flanagan, L., et al. Systematic review of care intervention studies for the management of incontinence and promotion of continence in older people in care homes with urinary incontinence as the primary focus (1966-2010). Geriatr Gerontol Int, 2012. 12: 600.
https://pubmed.ncbi.nlm.nih.gov/22672329/
582.Ostaszkiewicz, J., et al. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst Rev, 2004. 2004: CD002801.
https://pubmed.ncbi.nlm.nih.gov/15106179/
583.Rai, B.P., et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev, 2012. 12: CD003193.
https://pubmed.ncbi.nlm.nih.gov/23235594/
584.Anderson, C.A., et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev, 2015. 1: CD001843.
https://pubmed.ncbi.nlm.nih.gov/25602133/
585.Kannan, P., et al. Effectiveness of Pelvic Floor Muscle Training Alone and in Combination With Biofeedback, Electrical Stimulation, or Both Compared to Control for Urinary Incontinence in Men Following Prostatectomy: Systematic Review and Meta-Analysis. Phys Ther, 2018. 98: 932.
https://pubmed.ncbi.nlm.nih.gov/30137629/
586.Sciarra, A., et al. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. Int J Clin Pract, 2021. 75: e14208.
https://pubmed.ncbi.nlm.nih.gov/33811418/
587.Goonewardene, S.S., et al. A systematic review of PFE pre-prostatectomy. J Robot Surg, 2018.
12: 397.
https://pubmed.ncbi.nlm.nih.gov/29564692/
588.Primiceri, G., et al. Conservative management of urinary incontinence following robot-assisted radical prostatectomy. Miner Minerva Urol Nefrol, 2020. 72: 555.
https://pubmed.ncbi.nlm.nih.gov/32432436/
589.Dubbelman, Y., et al. The recovery of urinary continence after radical retropubic prostatectomy: a randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only. BJU Int, 2010. 106: 515.
https://pubmed.ncbi.nlm.nih.gov/20201841/
590.Moore, K.N., et al. Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology, 2008. 72: 1280.
https://pubmed.ncbi.nlm.nih.gov/18384853/
591.Goode, P.S., et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA, 2011. 305: 151.
https://pubmed.ncbi.nlm.nih.gov/21224456/
592.Glazener, C., et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet, 2011. 378: 328.
https://pubmed.ncbi.nlm.nih.gov/21741700/
593.Anan, G. et al. Preoperative pelvic floor muscle exercise for early continence after holmium laser enucleation of the prostate: a randomized controlled study. BMC Urol, 2020. 20: 3.
https://pubmed.ncbi.nlm.nih.gov/31973706/
594.Gomes, C.S., et al. The effects of Pilates method on pelvic floor muscle strength in patients with post-prostatectomy urinary incontinence: A randomized clinical trial. Neurourol Urodyn, 2018. 37: 346.
https://pubmed.ncbi.nlm.nih.gov/28464434/
595.Heydenreich, M. et al. Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial. Clin Rehabil, 2020. 34: 320.
https://pubmed.ncbi.nlm.nih.gov/31858823/
596.Soto Gonzalez, M., et al. Early 3-month treatment with comprehensive physical therapy program restores continence in urinary incontinence patients after radical prostatectomy: A randomized controlled trial. Neurourol Urodyn, 2020. 39: 1529.
https://pubmed.ncbi.nlm.nih.gov/32442334/
597.Farzinmehr, A., et al. A Comparative Study of Whole Body Vibration Training and Pelvic Floor Muscle Training on Women’s Stress Urinary Incontinence: Three- Month Follow- Up. J Family Reprod Health, 2015. 9: 147.
https://pubmed.ncbi.nlm.nih.gov/27047560/
598.Wang, C., et al. Extended nursing for the recovery of urinary functions and quality of life after robot-assisted laparoscopic radical prostatectomy: a randomized controlled trial. Support Care Cancer, 2018. 26: 1553.
https://pubmed.ncbi.nlm.nih.gov/29196816/
599.Pané-Alemany, R., et al. Efficacy of transcutaneous perineal electrostimulation versus intracavitary anal electrostimulation in the treatment of urinary incontinence after a radical prostatectomy: Randomized controlled trial. Neurourol Urodyn, 2021. 40: 1761.
https://pubmed.ncbi.nlm.nih.gov/34224598/
600.Berghmans, B., et al. Electrical stimulation with non-implanted electrodes for urinary incontinence in men. Cochrane Database Syst Rev, 2013: CD001202.
https://pubmed.ncbi.nlm.nih.gov/23740763/
601.Lim, R., et al. Efficacy of electromagnetic therapy for urinary incontinence: A systematic review. Neurourol Urodyn, 2015. 34: 713.
https://pubmed.ncbi.nlm.nih.gov/25251335/
602.Wallace, P.A., et al. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol, 2007. 197: 96 e1.
https://pubmed.ncbi.nlm.nih.gov/17618775/
603.Civic, D., et al. Re: Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial: K. M. Peters,
D. J. Carrico, R. A. Perez-Marrero, A. U. Khan, L. S. Wooldridge, G. L. Davis and S. A. MacDiarmid
J Urol 2010; 183: 1438-1443. J Urol, 2011. 185: 362; author reply 362.
https://pubmed.ncbi.nlm.nih.gov/21092997/
604.Ramírez-García, I., et al. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial. Neurourol Urodyn, 2019. 38: 261.
https://pubmed.ncbi.nlm.nih.gov/30311692/
605.Booth, J. et al. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review. Neurourol Urodyn, 2018. 37: 528.
https://pubmed.ncbi.nlm.nih.gov/28731583/
606.Wang, M., et al. Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J, 2020. 31: 2457.
https://pubmed.ncbi.nlm.nih.gov/32681345/
607.Chapple, C., et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int, 2014. 114: 418.
https://pubmed.ncbi.nlm.nih.gov/24552358/
608.Kaplan, S.A., et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract, 2014. 68: 1065.
https://pubmed.ncbi.nlm.nih.gov/24898471/
609.Bianco, F.J., et al. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.
J Urol, 2015. 193: 1305.
https://pubmed.ncbi.nlm.nih.gov/25281778/
610.Yang, R., et al. Efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy. J Int Med Res, 2017. 45: 2119.
https://pubmed.ncbi.nlm.nih.gov/28661264/
611.Chapple, C.R., et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn, 2014. 33: 17.
https://pubmed.ncbi.nlm.nih.gov/24127366/
612.Maman, K., et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol, 2014. 65: 755.
https://pubmed.ncbi.nlm.nih.gov/24275310/
613.MacDiarmid, S., et al. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy. J Urol, 2016. 196: 809.
https://pubmed.ncbi.nlm.nih.gov/27063854/
614.Su, S., et al. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Medicine (Baltimore), 2020. 99: e18802.
https://pubmed.ncbi.nlm.nih.gov/31977871/
615.Kotecha, P., et al. Use of Duloxetine for Postprostatectomy Stress Urinary Incontinence: A Systematic Review. Eur Urol Focus, 2021. 7: 618.
https://pubmed.ncbi.nlm.nih.gov/32605820/
616.Toia, B., et al. Bulking for stress urinary incontinence in men: A systematic review. Neurourol Urodyn, 2019. 38: 1804.
https://pubmed.ncbi.nlm.nih.gov/
617.Imamoglu, M.A., et al. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol, 2005. 47: 209.
https://pubmed.ncbi.nlm.nih.gov/15661416/
618.Sacco, E. et al. A propensity score-matching analysis comparing bulking agent with sling implantation for the treatment of postprostatectomy stress urinary incontinence. Neurourol Urodyn, 2019. 38: S57.
https://onlinelibrary.wiley.com/doi/10.1002/nau.24013
619.Nguyen, L., et al. The use of urethral bulking injections in post-prostatectomy stress urinary incontinence: A narrative review of the literature. Neurourol Urodyn, 2019. 38: 2060.
https://pubmed.ncbi.nlm.nih.gov/31432568/
620.Choinière, R., et al. Evaluation of Benefits and Harms of Surgical Treatments for Post-radical Prostatectomy Urinary Incontinence: A Systematic Review and Meta-analysis. Eur Urol Focus, 2021.
https://pubmed.ncbi.nlm.nih.gov/34563480/
621.Kowalik, C.R., et al. Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery. Neurourol Urodyn, 2018. 37: 339.
https://pubmed.ncbi.nlm.nih.gov/28452427/
622.Stothers, L., et al. Delayed hypersensitivity and systemic arthralgia following transurethral collagen injection for stress urinary incontinence. J Urol, 1998. 159: 1507.
https://pubmed.ncbi.nlm.nih.gov/9554343/
623.Malizia, A.A., Jr., et al. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). Jama, 1984. 251: 3277.
https://pubmed.ncbi.nlm.nih.gov/6374180/
624.Pannek, J., et al. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol, 2001. 166: 1350.
https://pubmed.ncbi.nlm.nih.gov/11547072/
625.Cornel, E.B., et al. Can advance transobturator sling suspension cure male urinary postoperative stress incontinence? J Urol, 2010. 183: 1459.
https://pubmed.ncbi.nlm.nih.gov/20172561/
626.Zeif, H.J., et al. The male sling for post-radical prostatectomy urinary incontinence: urethral compression versus urethral relocation or what is next? British J Med Surg Urol, 2010. 3: 134.
https://www.sciencedirect.com/science/article/abs/pii/S1875974210000248
627.Bole, R., et al. Narrative review of male urethral sling for post-prostatectomy stress incontinence: sling type, patient selection, and clinical applications. Transl Androl Urol, 2021. 10: 2682.
https://pubmed.ncbi.nlm.nih.gov/34295753/
628.Chen, Y.-C., et al. Surgical treatment for urinary incontinence after prostatectomy: A meta-analysis and systematic review. PLoS ONE, 2017. 12: e0130867.
https://pubmed.ncbi.nlm.nih.gov/28467435/
629.Guacheta Bomba, P.L., et al. Effectiveness of surgical management with an adjustable sling versus an artificial urinary sphincter in patients with severe urinary postprostatectomy incontinence: a systematic review and network meta-analysis. Ther Adv Urol, 2019. 11.
https://pubmed.ncbi.nlm.nih.gov/31632464/
630.Abrams, P., et al. Outcomes of a Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER). Eur Urol, 2021. 79: 812.
https://pubmed.ncbi.nlm.nih.gov/33551297/
631.Cornu, J.N., et al. Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int, 2011. 108: 236.
https://pubmed.ncbi.nlm.nih.gov/20955265/
632.Grabbert, M., et al. Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: Results of a prospective and multicenter study. Neurourol Urodyn, 2019. 38: 1973.
https://pubmed.ncbi.nlm.nih.gov/31297894/
633.Husch, T., et al. The AdVance and AdVanceXP male sling in urinary incontinence: is there a difference? World J Urol, 2018. 36: 1657.
https://pubmed.ncbi.nlm.nih.gov/29728764/
634.Malval, B., et al. Long-term outcomes of I-Stop TOMSTM male sling implantation for post-prostatectomy incontinence management. Prog Urol, 2017. 27: 1084.
https://pubmed.ncbi.nlm.nih.gov/29097039/
635.Silva, L.A.d., et al. Adjustable sling for the treatment of post-prostatectomy urinary incontinence: systematic review and meta-analysis. Einstein (Sao Paulo, Brazil), 2019. 17: eRW4508.
https://pubmed.ncbi.nlm.nih.gov/31553360/
636.Bauer, R.M., et al. Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology, 2011. 77: 474.
https://pubmed.ncbi.nlm.nih.gov/21167563/
637.Wright, H.C., et al. Transobturator sling for post-prostatectomy incontinence: radiation’s effect on efficacy/satisfaction. Can J Urol, 2017. 24: 8998.
https://pubmed.ncbi.nlm.nih.gov/28971786
638.Meisterhofer, K., et al. Male Slings for Postprostatectomy Incontinence: A Systematic Review and Meta-analysis. Eur Urol Focus, 2020. 6: 575.
https://pubmed.ncbi.nlm.nih.gov/30718160/
639.Abrams, P., et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn, 2010. 29: 213.
https://pubmed.ncbi.nlm.nih.gov/20025020/
640.Gill, B.C., et al. Patient perceived effectiveness of a new male sling as treatment for post-prostatectomy incontinence. J Urol, 2010. 183: 247.
https://pubmed.ncbi.nlm.nih.gov/19913826/
641.Rehder, P., et al. The 1 year outcome of the transobturator retroluminal repositioning sling in the treatment of male stress urinary incontinence. BJU Int, 2010. 106: 1668.
https://pubmed.ncbi.nlm.nih.gov/20518761/
642.Navalon-Monllor, V., et al. Long-term follow-up for the treatment of male urinary incontinence with the Remeex system. Actas Urol Esp, 2016. 40: 585.
https://pubmed.ncbi.nlm.nih.gov/27237411/
643.Shamout, S., et al. Short-term evaluation of the adjustable bulbourethral male sling for post-prostatectomy urinary incontinence. Low Urin Tract Symptoms, 2019. 11: O111.
https://pubmed.ncbi.nlm.nih.gov/29869450/
644.Esquinas, C., et al. Effectiveness of Adjustable Transobturator Male System (ATOMS®) to Treat Male Stress Incontinence: A Systematic Review and Meta-Analysis. Adv Ther, 2019. 36: 426.
https://pubmed.ncbi.nlm.nih.gov/30560525/
645.Lima, J.P., et al. Argus T® versus Advance® Sling for postprostatectomy urinary incontinence: A randomized clinical trial. Int Braz J Urol, 2016. 42: 531.
https://pubmed.ncbi.nlm.nih.gov/27286117/
646.Kim, J. Long term follow-up of readjustable urethral sling procedure (Remeex System) for male stress urinary incontinence. Neurourol Urodyn, 2011. 30: #209. [No abstract available].
647.Bochove-Overgaauw, D.M., et al. An adjustable sling for the treatment of all degrees of male stress urinary incontinence: retrospective evaluation of efficacy and complications after a minimal followup of 14 months. J Urol, 2011. 185: 1363.
https://pubmed.ncbi.nlm.nih.gov/21334683/
648.Dalpiaz, O., et al. Mid-term complications after placement of the male adjustable suburethral sling: a single center experience. J Urol, 2011. 186: 604.
https://pubmed.ncbi.nlm.nih.gov/21684559/
649.Loertzer, H., et al. Retropubic vs transobturator Argus adjustable male sling: Results from a multicenter study. Neurourol Urodyn, 2020. 39: 987.
https://pubmed.ncbi.nlm.nih.gov/32125722/
650.Abellan, F.J., et al. Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS®) and Adjustable Continence Therapy (ProACT) for male stress incontinence. PLoS ONE, 2019. 14: e0225762.
https://pubmed.ncbi.nlm.nih.gov/31790490/
651.Hubner, W.A., et al. Adjustable bulbourethral male sling: experience after 101 cases of moderate-to-severe male stress urinary incontinence. BJU Int, 2011. 107: 777.
https://pubmed.ncbi.nlm.nih.gov/20964801/
652.Muhlstadt, S., et al. Five-year experience with the adjustable transobturator male system for the treatment of male stress urinary incontinence: a single-center evaluation. World J Urol, 2017. 35: 145.
https://pubmed.ncbi.nlm.nih.gov/27156092/
653.Cestari, A., et al. Retropubic Intracorporeal Placement of a Suburethral Autologous Sling During Robot-Assisted Radical Prostatectomy to Improve Early Urinary Continence Recovery: Preliminary Data. J Endourol, 2015. 29: 1379.
https://pubmed.ncbi.nlm.nih.gov/26131781/
654.Kojima, Y., et al. Bladder neck sling suspension during robot-assisted radical prostatectomy to improve early return of urinary continence: a comparative analysis. Urology, 2014. 83: 632.
https://pubmed.ncbi.nlm.nih.gov/24387929/
655.Cestari, A., et al. Simple vs six-branches autologous suburethral sling during robot-assisted radical prostatectomy to improve early urinary continence recovery: prospective randomized study. J Robot Surg, 2017. 11: 415.
https://pubmed.ncbi.nlm.nih.gov/28078523/
656.Nguyen, H.G., et al. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol, 2017. 197: 369.
https://pubmed.ncbi.nlm.nih.gov/27693447/
657.Kretschmer, A., et al. Surgical Treatment of Male Postprostatectomy Incontinence: Current Concepts. Eur Urol Focus, 2017. 3: 364.
https://pubmed.ncbi.nlm.nih.gov/29174616/
658.Ostrowski, I., et al. Preliminary outcomes of the European multicentre experience with the ZSI 375 artificial urinary sphincter for treatment of stress urinary incontinence in men. Centr Eur J Urol, 2019. 72: 263.
https://pubmed.ncbi.nlm.nih.gov/31720028/
659.de Barros, E.G.C., et al. Artificial sphincter “BR - SL - AS 904” in the treatment of urinary incontinence after radical prostatectomy: efficacy, practicality and safety in a prospective and multicenter study. Int Braz J Urol, 2018. 44: 1215.
https://pubmed.ncbi.nlm.nih.gov/30325613/
660.Suh, Y.S., et al. Long-term outcomes of primary implantation and revisions of artificial urinary sphincter in men with stress urinary incontinence. Neurourol Urodyn, 2017. 36: 1930.
https://pubmed.ncbi.nlm.nih.gov/28169469/
661.Serra, A.C., et al. Prospective follow-up study of artificial urinary sphincter placement preserving the bulbospongiosus muscle. Neurourol Urodyn, 2017. 36: 1387.
https://pubmed.ncbi.nlm.nih.gov/27654121/
662.Viers, B.R., et al. Long-Term Quality of Life and Functional Outcomes among Primary and Secondary Artificial Urinary Sphincter Implantations in Men with Stress Urinary Incontinence. J Urol, 2016. 196: 838.
https://pubmed.ncbi.nlm.nih.gov/26997310/
663.Léon, P., et al. Long-term functional outcomes after artificial urinary sphincter implantation in men with stress urinary incontinence. BJU Int, 2015. 115: 951.
https://pubmed.ncbi.nlm.nih.gov/24958004/
664.Trigo Rocha, F., et al. A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. Urology, 2008. 71: 85.
https://pubmed.ncbi.nlm.nih.gov/18242371/
665.Lai, H.H., et al. Urodynamic testing in evaluation of postradical prostatectomy incontinence before artificial urinary sphincter implantation. Urology, 2009. 73: 1264.
https://pubmed.ncbi.nlm.nih.gov/19371935/
666.Queissert, F., et al. High/low-volume center experience predicts outcome of AMS 800 in male stress incontinence: Results of a large middle European multicenter case series. Neurourol Urodyn, 2020. 39: 1856.
https://pubmed.ncbi.nlm.nih.gov/32567709/
667.Dosanjh, A., et al. A national study of artificial urinary sphincter and male sling implantation after radical prostatectomy in England. BJU Int, 2020. 125: 467.
https://pubmed.ncbi.nlm.nih.gov/31755624/
668.Llorens, C., et al. Urinary artificial sphincter ZSI 375 for treatment of stress urinary incontinence in men: 5 and 7 years follow-up report. Urol J, 2017. 84: 263.
https://pubmed.ncbi.nlm.nih.gov/
669.Van der Aa, F., et al. The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male non-neurogenic incontinence. Eur Urol, 2013. 63: 681.
https://pubmed.ncbi.nlm.nih.gov/23219375/
670.Queissert, F., et al. Artificial Urinary Sphincter Cuff Size Predicts Outcome in Male Patients Treated for Stress Incontinence: Results of a Large Central European Multicenter Cohort Study. Int Neurourol J, 2019. 23: 219.
https://pubmed.ncbi.nlm.nih.gov/31607101/
671.Kaiho, Y., et al. Surgical and Patient Reported Outcomes of Artificial Urinary Sphincter Implantation: A Multicenter, Prospective, Observational Study. J Urol, 2018. 199: 245.
https://pubmed.ncbi.nlm.nih.gov/28823767/
672.Sacco, E., et al. Artificial urinary sphincter significantly better than fixed sling for moderate post-prostatectomy stress urinary incontinence: a propensity score-matched study. BJU Int, 2021. 127: 229.
https://pubmed.ncbi.nlm.nih.gov/32744793/
673.Larson, T., et al. Adjustable continence therapy (ProACT) for the treatment of male stress urinary incontinence: A systematic review and meta-analysis. Neurourol Urodyn, 2019. 38: 2051.
https://pubmed.ncbi.nlm.nih.gov/31429982/
674.Crivellaro, S., et al. Adjustable continence therapy (ProACT) and bone anchored male sling: Comparison of two new treatments of post prostatectomy incontinence. Int J Urol, 2008. 15: 910.
https://pubmed.ncbi.nlm.nih.gov/18761534/
675.Martens, F.M., et al. ProACT for stress urinary incontinence after radical prostatectomy. Urol Int, 2009. 82: 394.
https://pubmed.ncbi.nlm.nih.gov/19506404/
676.Roupret, M., et al. Management of stress urinary incontinence following prostate surgery with minimally invasive adjustable continence balloon implants: functional results from a single center prospective study. J Urol, 2011. 186: 198.
https://pubmed.ncbi.nlm.nih.gov/21575974/
677.Herschorn, S., et al. Surgical treatment of stress incontinence in men. Neurourol Urodyn, 2010.
29: 179.
https://pubmed.ncbi.nlm.nih.gov/20025026/
678.Gilling, P.J., et al. An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2-year follow-up. BJU Int, 2008. 102: 1426.
https://pubmed.ncbi.nlm.nih.gov/18564132/
679.Hubner, W.A., et al. Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. BJU Int, 2005. 96: 587.
https://pubmed.ncbi.nlm.nih.gov/16104915/
680.Duthie, J.B., et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev, 2011: CD005493.
https://pubmed.ncbi.nlm.nih.gov/22161392/
681.Mangera, A., et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol, 2011. 60: 784.
https://pubmed.ncbi.nlm.nih.gov/21782318/
682.Nitti, V.W., et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol, 2013.
189: 2186.
https://pubmed.ncbi.nlm.nih.gov/23246476/
683.Drake, M.J., et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int, 2017. 120: 611.
https://pubmed.ncbi.nlm.nih.gov/28670786/
684.Chughtai, B., et al. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol, 2014. 21: 7217.
https://pubmed.ncbi.nlm.nih.gov/24775575/
685.Faure Walker, N.A., et al. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. Urology, 2019. 123: 242.
https://pubmed.ncbi.nlm.nih.gov/30266377/
686.Bels, J., et al. Long-term Follow-up of Intravesical Onabotulinum Toxin-A Injections in Male Patients with Idiopathic Overactive Bladder: Comparing Surgery-naïve Patients and Patients After Prostate Surgery. Eur Urol Focus, 2020.
https://pubmed.ncbi.nlm.nih.gov/32919951/
687.Herschorn, S., et al. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. J Urol, 2017. 198: 167.
https://pubmed.ncbi.nlm.nih.gov/28161352/
688.Lozano-Ortega, G., et al. The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. Urology, 2019. 127: 1.
https://pubmed.ncbi.nlm.nih.gov/30790650/
689.Cui, Y., et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int, 2013. 91: 429.
https://pubmed.ncbi.nlm.nih.gov/23970316/
690.Mateu Arrom, L., et al. Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome. J Urol, 2020. 203: 392.
https://pubmed.ncbi.nlm.nih.gov/31479408/
691.He, Q., et al. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. Int Urogynecol J, 2021. 32: 477.
https://pubmed.ncbi.nlm.nih.gov/32661556/
692.Tutolo, M., et al. Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature. Eur Urol, 2018. 73: 406.
https://pubmed.ncbi.nlm.nih.gov/29336927/
693.Venn, S.N., et al. Long-term results of augmentation cystoplasty. Eur Urol, 1998. 34 Suppl 1: 40.
https://pubmed.ncbi.nlm.nih.gov/9705554/
694.Awad, S.A., et al. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol, 1998. 81: 569.
https://pubmed.ncbi.nlm.nih.gov/9598629/
695.El-Azab, A.S., et al. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty. Arab J Urol, 2013. 11: 344.
https://pubmed.ncbi.nlm.nih.gov/26558103/
696.Cody, J.D., et al. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev, 2012: CD003306.
https://pubmed.ncbi.nlm.nih.gov/22336788/
697.Hoen, L. ‘t, et al. Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review. Neurourol Urodyn, 2017. 36: 1685.